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A B S T R A C T
Background
Diseases caused by Streptococcus pneumoniae (S. pneumoniae) continue to cause substantial morbidity and mortality globally. Whilst
pneumococcal polysaccharide vaccines (PPV) have the potential to prevent disease and death, the degree of protection afforded against
various clinical endpoints and within different populations is uncertain.
Objectives
To assess the effectiveness of PPV in preventing disease or death in adults. Adverse events were not assessed.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2007, issue 2); MEDLINE
(January 1966 to June 2007); and EMBASE (1974 to June 2007).
Selection criteria
A) Randomised controlled trials (RCTs) comparing PPV with placebo, control vaccines, or no intervention.
B) Non-RCTs assessing PPV effectiveness against invasive pneumococcal disease (IPD).
Data collection and analysis
A) RCTs: trial quality assessment was conducted by two review authors and data extracted by three authors; odds ratios (OR) and 95%
confidence intervals (CI) were estimated using a random-effects model.
B) Non-RCTs: study quality, including measures to control for confounding, was assessed and data extracted by two review authors; OR
and 95% CI were calculated using a random-effects model following the conversion of each study outcome to a log OR and standard
error.
Main results
Twenty-two studies met our inclusion criteria (15 RCTs involving 48,656 participants and 7 non-RCTs involving 62,294 participants).
Meta-analysis of the RCTs found strong evidence of PPV efficacy against IPD with no statistical heterogeneity (OR 0.26, 95% CI 0.15
to 0.46; random-effects model, I-squared (I2) = 0%). Efficacy against all cause pneumonia was inconclusive with substantial statistical
heterogeneity (OR 0.71, 95% CI 0.52 to 0.97; random-effects model, I2 = 87.3%). PPV was not associated with substantial reductions
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in all-cause mortality (OR 0.87, 95% CI 0.69 to 1.10; random-effects model, I2 = 75.3%). Vaccine efficacy against primary outcomes
appeared poorer in adults with chronic illness but the difference was not statistically significant. Non-RCTs provided evidence for
protection against IPD in populations for whom the vaccine is currently utilised (OR 0.48, 95% CI 0.37 to 0.61; random-effects
model, I2 = 31.4%).
Authors’ conclusions
This meta-analysis provides evidence supporting the recommendation for PPV to prevent IPD in adults. The evidence from RCTs is
less clear with respect to adults with chronic illness. This might be because of lack of effect or lack of power in the studies. The meta-
analysis does not provide compelling evidence to support the routine use of PPV to prevent all-cause pneumonia or mortality.
P L A I N L A N G U A G E S U M M A R Y
Vaccination for preventing pneumococcal infection in adults
Streptococcus pneumoniae is responsible for illness and death in adults worldwide, usually from pneumonia and less often from invasive
pneumococcal disease (IPD). Vaccination (using pneumococcal polysaccharide vaccine (PPV)) in different populations might reduce
this illness and death. This review found 15 randomised controlled trials (RCTs) and seven non-RCTs (contributing outcomes for
culture-confirmed IPD only). Both RCTs and non-RCTs provided strong and consistent evidence of the effectiveness of PPV against
IPD. In these studies, vaccination might not afford as much protection in adults with chronic illness as it does for healthy adults.
B A C K G R O U N D
Description of the condition
Pneumococcal pneumonia and other diseases caused by Streptococ-
cus pneumoniae (S. pneumoniae) continue to cause substantial mor-
bidity andmortality throughout the world. Pneumonia is themost
common presentation of pneumococcal disease in adults. Bac-
teremic pneumonia is the most common cause of invasive pneu-
mococcal disease (IPD), accounting for 90% of all cases (Fedson
2004a). Mortality associated with pneumococcal pneumonia in
adults has remained unchanged at 25% over the past 40 years
(Kramer 1987; Pallares 1995).
Studies on the epidemiology of pneumococcal disease in high in-
come countries indicate that the highest incidence of disease is
among the very young and the elderly (Butler 2004). However,
some populations experience an increased disease incidence at a
young adult age, such as Australian Indigenous persons aged 15 to
49 years where the incidence of IPD is 10 times greater than the
rate innon-Indigenous populations (Menzies 2004). The epidemi-
ology of pneumococcal disease in adults in low income countries
has not been well described, but the global burden of pneumonia
in adults is likely to be significantly underestimated (Mulholland
1999).
The continuing burden of pneumococcal disease is worsened by
increasing numbers of people with chronic disease or HIV infec-
tion and an ageing population in many high income countries.
Antibiotic resistance continues to present a major threat to the
successful treatment of infections (Reacher 2000; Tomasz 1995).
In low income countries large numbers of people lack access to
basic curative health care but might be reached by vaccination
programmes.
Several population groups are at elevated risk of pneumococcal dis-
ease. Individuals with chronic disease (chronic lung disease, sickle
cell anemia, asplenic patients) or other conditions associated with
a compromised immune status have been shown to have increased
susceptibility to disease (Butler 2004). Other populations are at el-
evated risk due to environmental conditions including overcrowd-
ing, exposure to air pollutants such as smoke, and differences in
serotype distribution (Butler 2004). It is unknown whether the
higher rates of IPD in older adults in high income countries is due
to changes in the immune system or the presence of underlying
disease. A recent Cochrane Review (Granger 2006) failed to show
any protective efficacy of pneumococcal polysaccharide vaccine
(PPV) in patients with chronic obstructive pulmonary disease, al-
though only four trials were included in the meta-analysis.
Description of the intervention
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Nasopharyngeal pneumococcal colonisation plays an essential role
in the disease process. It is also recognised for its value in measur-
ing the potential benefits (or harms) of vaccination, including di-
rect effects on immunised individuals as well as indirect effects via
transmission between immunised and non-immunised individu-
als (herd effects). Changes in nasopharyngeal carriage in response
to pneumococcal conjugate vaccine (PCV) indicate a reduction in
carriage of vaccine serotypes in immunised individuals and, im-
portantly, a reduction in transmission to non-immunised popu-
lation. These herd effects are reflected in significant reductions in
rates of vaccine serotype invasive disease in the non-immunised
population (Whitney 2003). Conversely, replacement of vaccine
serotypes by carriage with serotypes not included in the vaccine
has been documented in both vaccinated and non-vaccinated in-
dividuals and has been variously reflected in rates of disease caused
by non-vaccine serotypes (Mackenzie 2005; Whitney 2003). In
contrast to PCV, herd effects of PPV have been poorly described,
possibly because the required threshold of vaccine coverage has
not been achieved in any studied population. There is a general
consensus that PPV does not confer protection against carriage
(Makela 2004). In view of the herd effects of PCV, and in order
to establish any evidence for this assumed consensus, it has been
decided to include this additional outcome in the meta-analysis.
Prior to the discovery of antibiotics, anti-sera to the polysaccharide
capsule was themost effective therapy for pneumococcal pneumo-
nia, reducing mortality to 5% if administered within 24 hours of
the onset of symptoms (Casadevall 1994). The discovery of differ-
ences in the structure of the polysaccharide capsule (serotypes) and
the need for anti-pneumococcal sera to be specific to each capsular
serotype led to the belief that the most effective protection against
pneumococcal disease was opsonisation of the polysaccharide coat
with antibody. There are over 90 different serotypes of S. pneumo-
niae, some are highly invasive whereas others rarely cause disease.
In addition, there is variation in the serotype distribution between
age groups and across different geographical populations (Fedson
2004a).
The search for a vaccine to protect against pneumococcal disease
began with the first whole cell vaccine trial involving miners in
South Africa, in 1911 (Wright 1914). FollowingMacLeod’s trial of
a four-valent PPV on military recruits in 1944 to 1945 (MacLeod
1945), a hexa-valent PPV became available for a short period,
from 1946 to 1948, but was withdrawn following the increased
use of penicillin. The continued high burden and severity of pneu-
mococcal disease despite the availability of antibiotics has led to
renewed calls for vaccine development and use. Trials of a six-va-
lent PPV and a 13-valent PPV among South African gold miners
(Austrian 1976a) and a 14-valent PPV in Papua New Guinean
highlanders (Riley 1977) showed strong vaccine efficacy against
bacteremic pneumonia. Where specified, these vaccines contained
50 µg of each purified capsular polysaccharide. A 14-valent PPV
was licensed for use in the United States in 1977; in 1983 this was
replaced by a 23-valent formulation, containing a reduced 25 µg
of each purified capsular polysaccharide, without additional pre-
licensure trials.
Although there is no known immunological correlate of protection
against pneumococcal disease, several groups (with some chronic
illnesses, immunocompromised conditions, and older adults) have
been identified as either poor responders to all or some of the
pneumococcal polysaccharide serotypes contained within the vac-
cine. Differences in the immunogenicity of 23-valent PPV have
also been noted across population groups (McMahon 1993) with
genetic factors also thought to influence antibody responses to the
pneumococcal capsular polysaccharides (Pandey 2000).
The 23-valent PPV has been utilised internationally to varying
extents, but mainly limited to older adults and adults with medi-
cal risk factors for IPD in high income countries (Fedson 1998).
This review updates the previous Cochrane Review (Dear 2003)
and addresses whether PPV is effective in all adult populations or
whether only some groups benefit.
O B J E C T I V E S
The primary aims of this review were to assess the efficacy and
effectiveness of PPV in preventing IPD, efficacy of PPV against
all-cause pneumonia, and efficacy against all-cause mortality in
adults. Secondary aims of the review were to assess vaccine efficacy
in preventing definitive and presumptive pneumococcal pneumo-
nia, death due to pneumonia or pneumococcal disease, and pneu-
mococcal nasopharyngeal colonisation.
M E T H O D S
Criteria for considering studies for this review
Types of studies
1. Prospective, randomised or quasi-randomised trials in
adults that compared PPV with placebo, control vaccines, or no
intervention.
2. Non-RCTs in adults that assessed pneumococcal vaccine
effectiveness against sterile site, culture confirmed IPD where the
trials were conducted as case-control studies, cohort, or indirect
cohort studies that made adjustments for important confounding
factors. Studies reporting outcomes according to International
Classification of Diseases codes have been excluded.
Types of participants
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Adults of either sex aged 16 years and above. Studies limited to
HIV-positive participants were excluded as these are the subject
of another Cochrane Review (Louie 2000).
Types of interventions
Vaccination with any PPV. Studies making the following com-
parisons were included: vaccine compared with placebo; vaccine
compared with no intervention; a combination of pneumococ-
cal vaccine with a non-pneumococcal vaccine compared with the
other vaccine given alone. Where reported, disease outcomes have
been limited to those occurring 14 days or more after vaccination.
Types of outcome measures
Primary outcomes
A. RCTs
A1. IPD: a pneumococcal infection with S. pneumoniae isolated
from a usually sterile body fluid.
A2. Pneumonia (all causes): a clinical history of lower respiratory
tract infection confirmed by the presence of a radiographic infil-
trate independent of the cause of pneumonia.
A3. Mortality (all causes).
Secondary outcomes
A4. IPD (as defined in A1): of a pneumococcal serotype included
in the vaccine administered.
A5. Definitive pneumococcal pneumonia: clinically and radio-
graphically confirmed pneumonia with S. pneumoniae isolated
from a usually sterile site.
A6. Definitive pneumococcal pneumonia (as defined in A5): of a
pneumococcal serotype included in the vaccine administered.
A7. Presumptive pneumococcal pneumonia: clinically and radio-
graphically confirmed pneumonia with S. pneumoniae isolated
from a culture of sputum or a nasal swab.
A8. Presumptive pneumococcal pneumonia (as defined in A7): of
a pneumococcal serotype included in the vaccine administered.
A9. Mortality due to pneumonia (pneumonia as defined in A2).
A10. Mortality due to pneumococcal infection (as defined in A1).
A11. Pneumococcal nasopharyngeal colonisation: defined as the
detection of S. pneumoniae isolated from a culture from a nose or
nasopharyngeal swab.
B. Non-RCTs
B1. IPD: a pneumococcal infection with S. pneumoniae isolated
from a usually sterile site.
B2. IPD (as defined in B1): of a pneumococcal serotype included
in the vaccine administered.
Search methods for identification of studies
Electronic searches
The initial review (Dear 2003) included electronic searches of
the Cochrane Central Register of Controlled Trials (CENTRAL)
(The Cochrane Library 2003, issue 2) which includes the Cochrane
Acute Respiratory Infections (ARI) Group Specialised Register;
MEDLINE (January 1966 to June 2003); and EMBASE (1974
to June 2003). Search terms included ’pneumococcal vaccine’
or ’pneumococcal immunisation’ and ’trials’ or ’controlled trials’.
Other search terms were not specified.
For this updated review, we searched the Cochrane Central Regis-
ter of Controlled Trials (CENTRAL) (TheCochrane Library 2007,
issue 2); MEDLINE (January 1966 to June 2007); and EMBASE
(1974 to June 2007). The followingMEDLINE search terms were
run over CENTRAL and adapted for EMBASE.
MEDLINE (OVID)
1 exp Pneumococcal Vaccines/
2 pneumococcal vaccine$.mp.
3 (pneumococcal adj (immunis$ or immuniz$)).mp.
4 exp Streptococcus pneumoniae/
5 exp Vaccination/
6 (immunis$ or immuniz$ or vaccin$).mp.
7 or/5-6
8 4 and 7
9 or/1-3,8
10 RANDOMISED CONTROLLED TRIAL.pt.
11 CONTROLLED CLINICAL TRIAL.pt.
12 RANDOMISED CONTROLLED TRIALS.sh.
13 RANDOM ALLOCATION.sh.
14 DOUBLE BLIND METHOD.sh.
15 SINGLE-BLIND METHOD.sh.
16 or/10-15
17 Animals/
18 Humans/
19 17 not 18
20 16 not 19
21 CLINICAL TRIAL.pt.
22 exp Clinical Trials/
23 (clin$ adj25 trial$).ti,ab.
24 ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or
mask$)).ti,ab.
25 PLACEBOS.sh.
26 placebo$.ti,ab.
27 random$.ti,ab.
28 or/21-27
29 28 not 19
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30 20 or 29
31 9 and 30
The following termswere used for reports of non-randomised trials
within MEDLINE:
1 exp Pneumococcal Vaccines/
2 pneumococcal vaccine$.mp.
3 (pneumococcal adj (immunis$ or immuniz$)).mp.
4 exp Streptococcus pneumoniae/
5 exp Vaccination/
6 (immunis$ or immuniz$ or vaccin$).mp.
7 or/5-6
8 4 and 7
9 or/1-3,8
10 exp Cohort Studies/
11 exp Case-Control Studies/
12 exp Intervention Studies/
13 exp Prospective Studies/
14 exp Longitudinal Studies/
15 observational stud$.mp
16 uncontrolled stud$.mp.
17 latin square$.mp.
18 factorial.mp.
19 Evaluation Studies.pt.
20 or/10-19
21 9 and 20
Searching other resources
The search also included handsearchingVaccine (from its first issue
to the end of 1995); contacting vaccine manufacturers to identify
any remaining published or unpublished randomised controlled
trials; searching bibliographies of previous meta-analyses of pneu-
mococcal vaccine (Fine 1994; Hutchison 1999); and contacting
authors of any other trials published within the previous 10 years.
The bibliographies of previous meta-analyses of pneumococcal
vaccine and newly retrieved trials were searched in order to iden-
tify further trials. Authors of published conference abstracts were
contacted to ensure publication of presented data had not been
included in a non-searched database. There were no language or
publication restrictions to the literature search.
Data collection and analysis
Trial quality assessment
Assessment of the quality of the identified RCTs was described
according to their quality of randomisation, expressed by conceal-
ment of participant allocation (adequate, unclear, or inadequate).
The quality of the trials was then assessed using the Jadad method
(Jadad 1996). The trialswere independently assessed by two review
authors and any inconsistency in the scores was discussed so as
to agree on a final score. Each trial was scored on the following
criteria.
Was the trial described as randomised?
Was the generation of the randomisation sequence described and
appropriate?
Was the trial described as double blind?
Was the double blinding method described and appropriate?
Was there a description of withdrawals and dropouts?
Thus each trial could score from zero to five points. The point
for randomisation was not given if a randomisation method was
described but was inappropriate. The point for double blinding
was not given if a blinding method was described but was inap-
propriate.
All non-RCTs identified were independently assessed by two re-
view authors. Assessment of the quality of the non-RCTswas based
on adequacy of control for confounding factors (including using
matching in case-control studies) and completeness of case ascer-
tainment.
Selection of studies
Two review authors independently reviewed the full text of studies
retrieved by the electronic searches for both the randomised con-
trolled trials (RCTs) and non-RCTs that appeared to meet inclu-
sion criteria from the abstract. They established whether the study
met inclusion criteria and had at least one of the pre-determined
outcomes (as defined above).
Data extraction and management
Data from the RCTs were independently extracted from the pub-
lished reports by three review authors (using standardised data ex-
traction forms) and by two review authors for the non-RCTs. The
updated review involved re-extracting all data from RCTs as the
outcomes from the previous review had been revised. Study details
and the outcome data were collected and are outlined in the table
’Characteristics of included studies’.
Subgroup analysis and investigation of heterogeneity
A. RCTs
Analysis of the RCTs was carried out inMetaview to estimate odds
ratios (OR) and 95% confidence intervals (CI). Random-effects
models were used. Publication bias was examined using funnel
plots.
Subgroup analysis was conducted according to pre-specified char-
acteristics of trials that were considered clinically relevant and
would lead to recommendations for vaccination according to pop-
ulations at risk of pneumococcal disease due to different fac-
tors. True pre-specification was not possible due to authors’ prior
knowledge of trials but was conducted prior to determining the
number of participants in each group.
Analysis was conducted for three subgroups of participants:
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1. otherwise healthy adults in low income countries.This
population group included otherwise healthy adults who were
likely to be at greater risk of pneumococcal disease than their
counterparts in high income countries due to environmental
factors such as overcrowding and exposure to smoke together
with likely differences in serotype distribution.
2. adults with chronic illness in high income countries.This
population group were likely to be at elevated susceptibility to
disease and potentially had suboptimal vaccine immunogenicity.
3. otherwise healthy adults in high income countries.This
population group included participants from high income
countries who were not recruited on the basis of underlying
disease. We refer to these participants as ’otherwise healthy
adults’ and expected that they may have a better immune
response to vaccination than their counterparts in subgroup ii).
This subgroup analysis was performed for the primary outcomes
that included the larger number of studies (at least 10).Differences
between subgroups were investigated according to the method de-
scribed by Deeks (Deeks 2001) whereby significance of differ-
ence between groups was measured by Chi2 = Chi2IPDAll - (Chi
2
IPDGrp1 + Chi2IPDGrp2 + Chi2IPDGrp3).
B. Non-RCTs
Analysis of the non-RCTs was carried out in Metaview following
the conversion of each study outcome to a log OR and standard
error. Random-effects models were used. Where results were also
presented as estimates of vaccine effectiveness this has been calcu-
lated as 100 (1 - OR).
Subgroup analysis of the non-RCTs was conducted according to
study type (case control or indirect cohort study compared to
cohort study) using themethods described byDeeks (Deeks2001).
Case control studies are thought to be more susceptible to bias
and, as such, may give an elevated protective effect.
Analyses were performed on two subgroups of participants from
non-RCTs:
1. studies on immunocompetent participants; and
2. studies on immunocompetent older adults.
Study participants were considered immunocompetent if they
were not severely immunocompromised. Unless they could be
identified within the study, non-RCTs that included immuno-
compromised participants (those with HIV/AIDS, haematologic
cancers, or receiving prednisolone) were excluded from this anal-
ysis. Study participants were considered to be immunocompetent
older adults if they met the immunocompetent definition (above)
and all study participants were above 55 years of age, or if adjusted
analysis for this age group was reported.
Sensitivity analysis
Sensitivity analysis was conducted for primary outcomes (IPD, all-
cause pneumonia, and all-cause mortality) through the exclusion
of studies with the lowest methodological quality score (Jadad
score = 0) and the exclusion of studies using influenza vaccine as a
control vaccine since this vaccine may potentially have a beneficial
effect on the outcomes of interest (Rivetti 2006).
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
A total of 1137 studies were considered for inclusion in the update
of this review. Of the studies included in the initial review (total
22), five studies were excluded as they did not meet the inclusion
criteria: one RCT (Honkanen 1999), and four non-RCTs (Butler
1993; Farr 1995; Forrester 1987; MMWR 2001). Details of the
rationale for these exclusions are listed in the ’Characteristics of
excluded studies’ table.
Five additional studies have been included in this update, one
was randomised (Alfageme 2006) and the remaining four were
non-randomised (Benin 2003; Dominguez 2005; Jackson 2003;
Vila-Corcoles 2006), bringing the total of included studies back to
22 (15 RCTs and seven non-RCTs). Further details on individual
trials are provided in the ’Characteristics of included studies’ table.
A. RCTs
The RCTs included in the meta-analysis were conducted among
diverse population groups, which we have classified into three sub-
groups. Firstly, otherwise healthy adults from low income coun-
tries; this group consisted of African mine workers (Austrian
1976a; Smit 1977a; Smit 1977b) and community dwelling adults
residing in the highlands of Papua NewGuinea (Riley 1977), con-
sidered to have been at elevated risk of disease due to overcrowding
and environmental factors. These studieswere conductedwith vac-
cines containing six to 14 pneumococcal polysaccharide serotypes.
The second group were those populations that were considered
to be at elevated risk of pneumococcal disease due to underlying
medical illnesses such as chronic obstructive pulmonary disease
(Alfageme 2006; Davis 1987; Leech 1987) or patients with bron-
chogenic carcinoma (Klastersky 1986). Simberkoff (Simberkoff
1986) recruited participants on the basis of age (> 55 years) and the
presence of underlying chronic illness. Given the number of deaths
in both participant groups, this group was considered very high
risk. Collectively,these studies utilised either the 14-valent or 23-
valent PPVs in developed country settings: Spain, USA, Canada,
and Belgium.
The third population group of the included RCTs was participants
in high income countrieswhowere not recruited on the basis of un-
derlying disease. These studies were conducted with vaccines con-
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taining two to 23-valent pneumococcal polysaccharide serotypes.
The studies included participants at elevated risk of pneumococcal
disease due to their age and place of residence, institution-based
in New York (Kaufman 1947), hospices or retirements homes in
France (Gaillat 1985); older adults aged 50 to 85 years with pre-
vious hospital admission for community-acquired pneumonia in
Sweden (Ortqvist 1998); and community-based older adults in
Finland (Koivula 1997). The two other trials were conducted in
the United States among participants whose ages were not spec-
ified: adult inpatients were recruited from a psychiatric hospital
(Austrian 1980a); and adults members were recruited from the
Kaiser Permanente Health Plan (Austrian 1980b).
The most commonly reported outcome from the RCTs was all-
cause radiologically confirmed pneumonia (13 studies) followed
by all-cause mortality (11 studies), definitive pneumococcal pneu-
monia (10 studies), and IPD (10 studies). Five studies reported on
vaccine type IPD and four studies reported outcomes on vaccine
type definitive pneumonia. Mortality due to pneumonia was re-
ported in seven studies and pneumococcal specific mortality was
reported in three studies. Pneumococcal nasopharyngeal coloni-
sation was an outcome in two of the included studies but was not
able to be included in this review due to incomplete reporting.
B. Non-RCTs
Five case control studies and two large cohort studies were in-
cluded in the meta-analysis of non-RCTs. They considered vac-
cines containing 14-valent and 23-valent pneumococcal polysac-
charide serotypes.
Three case control studies that were set in the United States in-
cluded participants aged from 18 years with medical conditions
that placed them at higher risk of pneumococcal disease or par-
ticipants were above 65 years of age (Benin 2003; Shapiro 1984;
Shapiro 1991). The other two case control studies related only to
older adults: Sims 1988 recruited immunocompetent adults from
55 years of age (United States); and Dominguez 2005 included
older adults from 65 years of age (Spain).
The two cohort studies both contained large numbers of partici-
pants aged 65 years and above. One assessed 47,365 members of a
Group Health Cooperative in the United States over a three year
period (Jackson 2003); the other followed up 11,241 community-
dwelling Spanish residents for just over three years (Vila-Corcoles
2006). Both of these studies considered the 23-valent PPV.
Risk of bias in included studies
Table 1 shows quality assessment scores of the RCTs using the
system of Jadad 1996. On the 0 to 5 scale, 8 of the 15 studies
scored 3 or better, and 6 scored 2 or worse. Studies conducted prior
to 1980 scored lower on the Jadad score than later trials. This time
trend was not apparent when only considering susceptibility to
bias according to allocation concealment. Other potential sources
of bias could not be fully assessed due to incomplete reporting,
according to the CONSORT statement (Moher 2001).
The susceptibility of the case control studies to bias has been as-
sessed according to the adequacy of matching for confounding
factors and the completeness of follow up. The five case control
studies matched participants according to the presence of under-
lying disease (severity and number of conditions) and date of hos-
pital admission. All studies apart from Sims (Sims 1988) reported
matching according to age.
Both cohort studies followed participants for three years and con-
trolled for age, sex, and underlying medical conditions; they in-
cluded compromised immune status, smoking status, and in-
fluenza vaccination status in the model of effectiveness of PPV.
Vaccination was a time variable factor and participants were con-
sidered to be vaccinated 14 days following vaccine administration.
Effects of interventions
A. RCTs
Outcome A1. Invasive pneumococcal disease (IPD)
Ten studies involving 35,483 participants were included for this
outcome with 15 events in the vaccinated group and 60 events
in the control group. PPV reduced the risk of all IPD with a
pooled estimated OR of 0.26 (95% CI 0.15 to 0.46; random-
effects model). This correlated to a protective vaccine efficacy of
74% (95% CI 56 to 85). Statistical heterogeneity was not present
(I2 = 0%, P = 0.48).
Subgroups: outcome A1
(i) Otherwise healthy adults in low income countries
Riley was the only study included in this subgroup analysis, in-
volving 5373 participants with two events in the vaccinated group
compared to 14 events in the control group. There was evidence
of protective efficacy against IPD for this subgroup with OR 0.14
(95% CI 0.03 to 0.61).
(ii) Adults with chronic disease in high income countries
Five studies involving 3230 participants were included in this sub-
group analysis with four events in the vaccinated group compared
to two events in the control group. There was no evidence of pro-
tective efficacy (or any harm) from vaccination against IPD in this
subgroup. However, as demonstrated by the large CIs, there was
a lack of power to demonstrate a significant difference between
the vaccinated and the control groups (OR 1.56, 95% CI 0.35 to
6.94; random-effects model, I2 = 0%).
(iii) Otherwise healthy adults in high income countries
Four studies involving 26,880 participants were included in this
subgroup analysis with nine events in the vaccinated group and
44 events in the control group. There was evidence of protective
efficacy against IPD in this subgroup (OR 0.20, 95% CI 0.10 to
0.41; random-effects model, I2 = 0%).
The difference between the heterogeneity for all studies compared
to subgroups i, ii, and iii was statistically significant (Chi2 6.66,
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1 df, P < 0.01) indicating that the pooled estimate may not be
representative for each population group.
Outcome A2. Pneumonia (all causes)
Thirteen studies involving 45,783 participants were included in
this outcome with 835 events in the vaccinated group and 1350
events in the control group. PPV was shown to be effective against
all-cause pneumonia with a pooled estimated OR of 0.71 (95%
CI 0.52 to 0.97; random-effects model). However, there was a
high level of statistical heterogeneity present amongst the included
studies (I2 = 87.3%, P < 0.00001).
Subgroups: outcome A2.
(i) Adults in low income countries
Four studies involving 14,562 participants were included in this
subgroup analysis with 158 events in the vaccinated group com-
pared to 548 events in the control group. Pooled estimates showed
evidence of protective efficacy against all-cause pneumonia in this
population subgroup (OR 0.54, 95% CI 0.43 to 0.67; random-
effects model, I2 = 19.4%).
(ii) Adults with chronic illness in high income countries
Four studies involving 3071 participants were included in this
subgroup analysis with 90 events in the vaccinated group com-
pared to 88 events in the control group. As with other outcomes in
this population subgroup, wide CIs highlighted the lack of power
to demonstrate protective efficacy (or lack thereof ) against all-
cause pneumonia (OR 0.97, 95%CI 0.65 to 1.46; random-effects
model, I2 = 24.9%).
(iii) Adults in high income countries
Five studies involving 28,180 participants were included in this
subgroup analysis with 587 events in the vaccinated group and 714
events in the control group. There was no evidence of protective
efficacy against all-cause pneumonia for this sub-group although
it again should be noted that the CIs were wide (OR 0.74, 95%CI
0.43 to 1.27; random-effects model). There was also a high level
of statistical heterogeneity present (I2 = 93.8%, P < 0.00001).
As with IPD, the difference between the heterogeneity for all stud-
ies compared to groups i, ii, and iii was statistically significant (Chi
2 22.25, 2 df, P < 0.001), indicating that the pooled estimate may
not be representative for each population group.
Outcome A3. Mortality (all causes)
Eleven studies involving 45,609 participants were included in this
outcome with 899 events in the vaccinated group and 927 in the
control group. There was no evidence of protective efficacy against
all-cause mortality, with a pooled estimated OR of 0.87 (95% CI
0.69 to 1.10; random-effects model). A high level of statistical
heterogeneity was present (I2 = 75.3%, P < 0.0001).
Subgroups: outcome A3
(i) Adults in low income countries
Riley was the only study included in this subgroup, involving
11,958 participants with 133 events in the vaccine group and 170
in the control group (OR 0.79, 95% CI 0.62 to 0.99).
(ii) Adults with chronic illness in high income countries
Four studies involving 2634 participants were included in this sub-
group analysis with 233 events in the vaccinated group compared
to 199 events in the control group. Whilst there were more deaths
in the vaccinated group than in the control group the pooled es-
timate failed to demonstrate protective efficacy (or harm) in this
subgroup (OR 1.04, 95% CI 0.66 to 1.64; random-effects model,
I2 = 31.5%).
(iii) Adults in high income countries
Six studies involving 31,017 participants were included in this
subgroup analysis with 533 events in the vaccinated group and 558
events in the control group. There was no evidence of a protective
effect against all-cause mortality with a pooled estimated OR of
0.84 (95% CI 0.61 to 1.17; random-effects model, I2 = 81.6%).
As with IPD and all-cause pneumonia, the difference between the
heterogeneity for all studies compared to groups i, ii, and iii was
statistically significant (Chi2 8.98, 1 df, P < 0.05), indicating that
the pooled estimate may not be representative for each population
group.
Secondary outcomes
IPD (subgroups)
Outcome A4. Vaccine-type IPD
Five studies involving 31,223 participants considered vaccine-type
IPD,with 14 events in the vaccinated group and 140 in the control
group. The pooled estimate showed vaccination to be effective
for this very specific outcome (OR 0.18, 95% CI 0.10 to 0.31).
Statistical heterogeneity was absent (I2 = 0%, P = 0.70).
Outcome A5. Definitive pneumococcal pneumonia
Ten studies involving 35,483 participants assessed this outcome
with 15 events in the vaccinated group compared to 60 events in
the control group. PPV reduced the risk of definitive pneumococ-
cal pneumonia, pooled estimated OR of 0.26 (95% CI 0.15 to
0.46; random-effects model). The protective vaccine efficacy of
74% (95% CI 54 to 85) was very similar to the size of the effect
for outcome A1, which is likely to be due to the large amount
of overlap for studies contributing to both outcomes. Statistically
heterogeneity was absent (I2 = 0%, P = 0.48).
Outcome A6. Definitive PPV (vaccine-types only)
Four studies involving 30,561 participants considered vaccine-
type definitive pneumococcal pneumonia, with three events in
the vaccinated group and 30 events in the control group. The
pooled estimate showed the vaccine to be highly effective for this
outcome (OR 0.13, 95%CI 0.05 to 0.38; random-effects model).
Statistically heterogeneity was absent (I2 = 0%, P = 0.92).
All-cause pneumonia (subgroups)
Outcome A7. Presumptive pneumococcal pneumonia
Eight studies involving 19,329 participants were included in this
outcome with 86 events in the vaccinated group and 239 in the
control group. The pooled estimate showed the vaccine to be ef-
fective against this outcome (OR 0.47, 95% CI 0.23 to 0.99;
random-effects model). As with all-cause pneumonia, a high level
of statistically heterogeneity was present among the studies in-
cluded for presumptive pneumococcal pneumonia (I2 = 77.7%, P
< 0.0001).
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Outcome A8. Presumptive pneumococcal pneumonia (vaccine-types
only)
Five studies involving 18,568 participants were included in this
outcome with 19 events in the vaccinated group and 130 in the
control group. The pooled estimate showed vaccination was ef-
fective against this outcome with an OR of 0.27 (95% CI 0.08
to 0.87; random-effects model). Again a high level of statistically
heterogeneity was present (I2 = 69.6%, P = 01).
All-cause mortality (subgroups)
Outcome A9. Mortality due to pneumonia
Seven studies involving 28,939 participants were included in this
outcomewith 111 events in the vaccinated group and182 events in
the control group. However, the pooled estimate failed to demon-
strate protective efficacy against pneumonia relatedmortality with
a high level of statistical heterogeneity again present (OR 0.75,
95% CI 0.39 to 1.43; random-effects model; I2 = 77.9%).
Outcome A10. Mortality due to pneumococcal infection
Three studies involving 2445 participants were included in this
outcome with five events in the vaccinated group compared to one
event in the control group. Given the small number of events for
the sample size, there was insufficient power to demonstrate either
a reduction or increase in the risk of death from pneumococcal
infection among those who had been vaccinated (OR 2.51, 95%
CI 0.45 to 14.13; random-effects model; I2 = 0%).
Colonisation
Outcome A11. Pneumococcal nasopharyngeal colonisation
Although two studies reported outcomes for pneumococcal na-
sopharyngeal colonisation (Riley 1977; Simberkoff 1986) neither
could be included in the meta-analysis of this outcome. Riley re-
ported on a subgroup of healthy persons (151/2713 vaccine re-
cipients and 181/2660 placebo recipients) but gave no details on
how this subgroup had been selected. Simberkoff 1986 reported
data on 10,961 throat swabs taken from 2295 participants. Fifty-
four vaccine recipients and 56 placebo recipients were reported as
having transient colonisation but no details were given for preva-
lence of colonisation across the two groups for one time period.
Sensitivity analysis on RCTs
Quality score
For the sensitivity analysis based on quality score, only Kaufman
scored 0 on the Jadad score. Removing Kaufman from the meta-
analysis reduced the effect size for IPD and definitive pneumo-
coccal pneumonia (all types and vaccine types) but the protec-
tive effect remained significant. However, the removal of Kaufman
caused the significance of the effect to be lost for all-cause pneu-
monia (a less specific outcome than invasive disease). All-cause
mortality remained nonsignificant with a point estimate OR of 1.
Outcome A1. IPD
OR 0.34 (95% CI 0.14 to 0.82; random-effects model, I2 = 0%).
Outcome A2. All-cause pneumonia
OR 0.78 (95% CI 0.59 to 1.03; random-effects model, I2 =
80.8%).
Outcome A3. All-cause mortality
OR 1.00 (95% CI 0.87 to 1.15; random-effects model, I2 =
30.2%).
Influenza vaccine as a control
Three included studies used influenza vaccine. Two (Leech 1987;
Koivula 1997) gave the vaccine to both PPV intervention and
control participants. Gaillat (Gaillat 1985) was the only study
included in themeta-analysis that used influenza vaccine in control
participants only. Exclusion of this study narrowed the CI around
the estimate of protective effects of PPV against IPD. In contrast,
the significance of the effect against all-cause pneumonia was lost
once this study was excluded; the result for all-cause mortality was
only slightly affected.
Outcome A1. IPD
OR0.28 (95%CI 0.14 to 0.54; random-effectsmodel, I2 = 7.4%).
Outcome A2. All-cause pneumonia
OR 0.75 (95% CI 0.55 to 1.02; random-effects model, I2 =
87.8%).
Outcome A3. All-cause mortality
OR 0.84 (95% CI 0.65 to 1.10; random-effects model, I2 =
76.7%).
Publication (small study) bias
Publication bias was assessed using funnel plots and was presented
for the three primary outcomes of IPD, all-cause pneumonia, and
all-cause mortality. For each of these outcomes the funnel plots
were asymmetrical.
The funnel plot of studies contributing to the outcome of IPD
(Figure 1) showed asymmetry around the pooled point estimate.
However, it was not the smaller studies contributing larger treat-
ment effects and, therefore, asymmetrymay be due to other factors
such as heterogeneity between the population groups.
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Figure 1. Funnel plot for outcome 1. Invasive pneumococcal disease
The funnel plot of studies contributing to the outcome of all-
cause pneumonia (Figure 2) also showed asymmetry around the
pooled point estimate. There was an absence of smaller studies
contributing less effective outcomes. This did not appear to be
having a large impact on the pooled result as the larger studies
appeared to be symmetrical around no effect.
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Figure 2. Funnel plot for outcome 2. Pneumonia, all causes
The funnel plot of studies contributing to the outcome of all-cause
mortality (Figure 3) also showed asymmetry around the pooled
point estimate. Kaufman was a clear outlier, and two other smaller
studies show a larger effect, but again these studies did not appear
to have a large impact on the pooled results.
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Figure 3. Funnel plot for outcome 3. Mortality, all causes
B. Non-RCTs
Outcome B1. IPD
Seven studies were included in this outcome. PPV reduced the risk
of all IPD with a pooled estimate OR of 0.48 (95% CI 0.37 to
0.61; random-effects model). Statistically heterogeneity was not
present (I2 = 31.4%, P = 0.19).
Subgroup outcome B1. Immunocompetent
A subgroup analysis of immunocompetent participants included
six studies. PPV reduced the risk of all IPD in immunocompetent
adults with a pooled estimated OR of 0.41 (95% CI 0.32 to 0.52;
random-effects model). Statistical heterogeneity was absent (I2 =
18%, P = 0.30).
Subgroup outcome B1. Immunocompetent older adults
A subgroup analysis of immunocompetent older adults included
five studies. PPV reduced the risk of all IPD in immunocompetent
older adults with a pooled estimated OR of 0.32 (95% CI 0.22 to
0.47; random-effects model). Statistical heterogeneity was absent
(I2 = 0%, P = 0.68).
Subgroup analysis of study type
Subgroup analysis for IPD (all types) was conducted by study type
(case control or cohort). For case control studies, the pooled esti-
mate of vaccine effectiveness was not significantly different from
that determined from the cohort studies (OR 0.47, 95% CI 0.32
to 0.68; and OR 0.57, 95% CI 0.36 to 0.89, respectively). The
difference between the heterogeneity for all studies compared to
case control and cohort studies did not reach statistical significance
(Chi2 2.13, 1 df, P > 0.1).
Outcome B2. Vaccine-type IPD
Three studies were included in this outcome, with a pooled esti-
mated OR of 0.45 (95% CI 0.38 to 0.54; random-effects model;
I2 = 0%). The estimate for this outcome was similar to that for all
studies, although with a narrower CI.
Subgroup outcome B2. Immunocompetent
Of the two studies that considered vaccine-type IPD in immuno-
competent participants, pooled results showed an OR of 0.40
(95% CI 0.29 to 0.54; random-effects model; I2 = 0%).
Subgroup outcome B2. Immunocompetent older adults
Only one study reported on vaccine-type IPD in immunocompe-
tent older adults, with a nonsignificant protective effect (OR 0.66,
95% CI 0.14 to 3.03).
D I S C U S S I O N
This review aimed to determine the efficacy of the PPV, a vaccine
that has been licensed for 30 years, in adults. Given that most large
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RCTs had been conducted in populations with significant differ-
ences in disease susceptibility and serotype distribution, the clini-
cal relevance to adult populations today appears to be uncertain.
We have attempted to define clinically relevant primary outcomes
and analysis was conducted in distinct populations groups that are
likely to differ in disease susceptibility and disease exposure.
Previous meta-analyses
In addition to the previous Cochrane review (Dear 2003), at least
seven previous meta-analyses of PPV in adults have been pub-
lished. However, depending on the selection criteria, results from
these meta-analyses have been variable and controversy about the
effectiveness and value of the vaccine persists (Hirschmann 1994;
Ruben 1995).
Cornu (Cornu 2001),Moore (Moore 2000), and Fine (Fine 1994)
concluded that the vaccine was effective against bacteremic pneu-
mococcal pneumonia in ’low risk’ healthy adults, but the RCTs
failed to demonstrate vaccine efficacy in those at ’high risk’, a
heterogeneous group which included older adults (55 years and
above), those with chronic disease, or the immunosuppressed.Our
results also failed to show evidence for protective efficacy in adults
with chronic illness (discussed below). However, we have further
refined this assessment and have found evidence of efficacy against
IPD amongst otherwise healthy adults in developed country set-
tings. This population consisted predominantly of older adults
and institutionalised people.
Hutchison (Hutchison 1999) concluded that there was no evi-
dence that the vaccine was less efficacious for older adults (55 years
and above), institutionalised people or people with chronic dis-
ease. We disagree with this conclusion. Whilst we did not directly
measure vaccine efficacy against older adults or institutionalised
people, the results of our meta-analysis highlight apparent differ-
ences in efficacy amongst those participants selected on the basis
of chronic illness, as will be discussed later.
Watson (Watson 2002) found the vaccine was effective against
mortality and all-cause pneumonia in non-industrialised coun-
tries but not in industrialised countries, and noted that the small
numbers of cases of pneumococcal bacteremia made it difficult
to draw any firm conclusions for this outcome. Like Watson, our
results highlight differences in vaccine efficacy amongst different
population groups. Of particular note is the absence of hetero-
geneity within the population subgroups where IPD has been the
outcome of interest, but when these subgroups where compared
against the total population there was strong evidence of hetero-
geneity suggesting the pooled estimate may not be representative
of each population group.
Puig-Barbera (Puig-Barbera 2002) concluded there was no evi-
dence supporting pneumococcal vaccine effectiveness to reduce or
avoid S. pneumoniae disease in older adults (55 years and above)
but this meta-analysis lacked power to adequately assess this out-
come with only four RCTs included.
Conaty (Conaty 2004) conducted a systematic review of non-
RCTs and compared results with those from RCTs, finding ele-
vated point estimates of effectiveness from non-RCTs and non-
significant results from pooled RCTs. Like Conaty, and as with the
previous Cochrane Review, this update again includes non-RCTs
and shows supportive evidence of effectiveness against IPD. In
contrast to both of these meta-analyses however, our updated re-
view also demonstrates protective efficacy against IPD frompooled
RCTs.
IPD
This meta-analysis demonstrates strong evidence of protection
against IPD, with a correlate of efficacy from the RCTs of 74%
(95% CI 56% to 85%). This result remained robust in sensitivity
analyses, either through the removal of Kaufman (the study with
the poorest quality score) or Gaillat (the study that included in-
fluenza vaccine as the control).
Although therewas no statistical heterogeneitywhen all RCTswere
considered, there was a statistical difference (P < 0.01) between
the heterogeneity of the studies conducted among different pop-
ulation groups (otherwise healthy adults in low income countries,
adults with chronic illness in high income countries, and other-
wise healthy adults in high income countries). This indicates that
the estimate of efficacy generated from pooling all of the studies is
not representative for each of these population groups. In particu-
lar, vaccine efficacy amongst the subgroup of adults with chronic
disease appears poor in comparison to that of otherwise healthy
adults, in developed or low income countries. Whilst there was
insufficient power to demonstrate protective efficacy among the
subgroup of adults with chronic disease, it should be noted that
the disease risk amongst the control group was 124 per 100,000
population (2/1619). This is within the general estimate of IPD
for older adults (50 cases per 100,000 population) (Fedson 1999)
and indicates these studies are underpowered due to the number
of participants recruited rather than low disease incidence. Evi-
dence for vaccine efficacy for IPD in this subgroup population is
considered in the non-RCTs.
The inclusion of non-RCTs in this meta-analysis provides a valu-
able contribution to the understanding of the effectiveness of the
PPV, used more recently in large population groups for whom the
vaccine is currently recommended. We have refined this compo-
nent of the review from that undertaken initially (Dear 2003) by
limiting non-RCTs to those including adjustment for important
confounding factors. The meta-analysis of the non-RCTs demon-
strated protective efficacy for IPD with a pooled estimate corre-
sponding to a slightly lower measure of vaccine effectiveness of
52% (95% CI 37% to 61%) for all serotypes and 55% (95% CI
38% to 54%) for vaccine-type disease.
Effectiveness among both immunocompetent adults and im-
munocompetent older adults was also shown, with a nonsignif-
icantly higher estimate of effectiveness of 59% for all serotypes
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(95%CI 48% to 68%). We assessed case control studies separately
from cohort studies and showed that the estimate of effectiveness
from pooled case control studies, at 53% (95% CI 32% to 68%),
was not dissimilar to that obtained from two large cohort studies
(43%, 95% CI 11% to 64%).
The case control studies had similar estimates for vaccine effective-
ness (70%, 67%, and 70%) with the exception of Benin’s study
among Navajo adults (Benin 2003). That study, involving persons
aged from 18 years who had a medical condition that placed them
at higher risk of pneumococcal disease or others from age 65 years,
found vaccine effectiveness of only 27%. The inferior estimate of
effectiveness among Navajo adults may be due to population char-
acteristics. It was reported that 75% of cases and 78% of controls
were assigned as risk level 2 (alcoholism, diabetes, chronic cardiac,
lung, renal, and liver disease). This is higher than the equivalent
disease risk ratings of the other case control studies. Alcoholism in
particular is very prevalent in participants in Benin’s study (43%
and 45% of cases and controls), which has been associated with
poor vaccine immunogenicity (Butler 1993) and vaccine failures
(Hanna 2000; McMahon 1993).
Both cohort studies report very similar multivariate adjusted haz-
ard ratios for all-type IPD with a Jackson Hazard Ratio (HR) of
0.56 (95% CI 0.33 to 0.93) and Vila-Corcoles HR of 0.60 (95%
CI 0.22 to 1.65). Both studies adjusted for receipt of influenza
vaccination.
All-cause pneumonia
All-cause pneumonia is the most reported outcome in this review,
with data from 13 RCTs providing an apparent protective effi-
cacy of 29% (95% CI 3% to 48%). Population groups of other-
wise healthy adults in low income countries, adults with chronic
illness and otherwise healthy adults from high income countries
were considered for the outcome of all-cause pneumonia. The size
of this protective benefit appears to be variable across different
populations, with adults in low income countries being the only
population group showing a protective effect with the upper con-
fidence limit below one. The difference between the heterogeneity
of these groups compared to the total pooled estimate was sta-
tistically significant (P < 0.001). Again, this suggests the overall
estimate of effectiveness is not applicable to all population groups,
who are at different risk and susceptibility to disease. And again, it
appears that the population group of adults with chronic illness in
low income countries appear to have the poorest vaccine efficacy.
Similar rates of pneumonia among each of the control groups is
found ((i) 620/10,000; (ii) 578/10,000, and (iii) 518/10,000) and
lack of power in the group of adults with chronic illness is likely
to be due to participant numbers.
Watson (Watson 2002) has suggested that the proportion of pneu-
monia due to S. pneumoniae in the population under study may be
the critical factor in demonstrating an effect against all-cause pneu-
monia. Those populations where a high proportion of pneumonia
is due to S. pneumoniae would be more likely to show a reduction
in all-cause pneumonia due to vaccination. However, ascertain-
ing the proportion of pneumonia which is due to S. pneumoniae
is problematic (Fedson 2004b). Among the included RCTs, the
proportion of control participants developing pneumonia of any
cause had a population rate of disease incidence that varied from
15/1000 to 190.5/1000 population. The proportion of pneumo-
nia in control patients able to be confirmed as definitive pneumo-
coccal pneumonia also differed considerably, from 0% to 35%.
With the upper limit of the confidence interval at 0.97, exclud-
ing any study from this analysis results in a loss of significance
(including sensitivity analysis of Kaufman and Gaillat). It should
be acknowledged that the meta-analysis is inadequately powered
to exclude a protective efficacy less than 48%. This has been a
consistent criticism of previous meta-analyses that remains valid
in this updated review.
All-cause mortality
This meta-analysis has failed to demonstrate evidence for pneu-
mococcal polysaccharide vaccination effectiveness against mortal-
ity (all cause or pneumococcal related). All-cause mortality was re-
ported in 11 studies with no evidence of a protective benefit from
the meta-analysis (OR 0.87, 95% CI 0.69 to 1.10). The statistical
heterogeneity (P < 0.0001) of these pooled studies was again in-
vestigated by population group.We found the differences between
otherwise healthy adults in low income countries, adults with
chronic illness in high income countries, and otherwise healthy
adults in high income countries to be significant (P < 0.05), sug-
gesting that the pooled estimate of effectiveness is not applicable
to all population groups at different levels of risk and susceptibil-
ity to disease. It should be acknowledged that the meta-analysis
is inadequately powered to exclude a protective efficacy less than
31% or a harmful effect less than 10%.
The use of influenza vaccine in three included studies may have in-
fluenced the ability of this meta-analysis to determine the efficacy
of PPV against all-cause mortality. Gaillat administered influenza
vaccine to control participants only, with 232/937 deaths in the
PPV group compared to 175/749 in the control group. The re-
moval of this study had only a slight effect on the pooled estimate
of all trials in sensitivity analysis. Leech and Koivula gave influenza
vaccine to both PPV intervention and control participants thereby
only having the ability to show the incremental benefit of PPV
against all-cause mortality.
Subgroup analysis
Otherwise healthy adults in low income countries
The combined studies from this relatively homogenous subgroup
of young African miners and Papua New Guinean Highlanders
consistently demonstrate elevated vaccine efficacy against various
outcomes. Of note, vaccine efficacy has been demonstrated for
all-cause pneumonia (four studies) and all-cause mortality (one
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study) for this population only, highlighting the potential bene-
fits of increased uptake in such populations. It is also important
to highlight that the settings of these trials meant pneumococcal
disease was likely to be caused by a limited number of serotypes,
particularly in the mines, where pneumococcal outbreaks were a
significant cause of mortality. The effectiveness of the pneumococ-
cal polysaccharide vaccine in adults in low income countries today
would depend on several factors including circulating serotypes,
vaccine immunogenicity according to population health status,
susceptibility to disease, and risk of exposure.
Adults with chronic illness in high income countries
The subgroup analysis of RCTs in adults recruited on the basis of
the presence of chronic illness in high income countries consis-
tently failed to demonstrate evidence of protective benefit of vac-
cination. For each of the outcomes included in subgroup analysis
there are few events in either the intervention or control group
and CI are wide, indicating that the combined studies remain un-
derpowered. Whilst our review incorporated observational stud-
ies which included control for potential confounding factors such
as chronic disease, we did not directly assess vaccine effectiveness
against IPD for the chronic disease group.
Otherwise healthy adults in high income countries
The combined studies for this subgroup included participants re-
cruited on the basis of older age or who were likely to be a disad-
vantaged population in high income countries and demonstrated
consistent evidence for protection against IPD. However, for the
outcomes of all-cause pneumonia and all-cause mortality, statisti-
cal heterogeneity was present. The heterogeneity within all-cause
pneumonia appears to be predominantly fromKaufman andGail-
lat. The remaining three studies do not show evidence for pro-
tection against this outcome. The pooled estimate for all-cause
mortality is also statistically heterogeneous, with Kaufman being
the only study to show protective benefit. Again, the remaining
five studies do not show any evidence for protection against death
within this population group.
Vaccine valency
It would be misleading to consider vaccine valency in isolation
of other significant factors in order to explain the differences in
vaccine efficacy from RCTs. Included RCTs consider eight dif-
ferent vaccine valencies, ranging from two to 23 serotypes. The
most frequently used vaccine was the 14-valent, considered in six
trials, and only two trials (Alfageme 2006; Ortqvist 1998) con-
sidered the 23-valent formulation, which is the vaccine currently
licensed. It was not possible to compare the trials using lower-
valency vaccines with trials using higher-valency vaccines due to
considerable differences in population settings (likely differences
in exposure and serotype distribution), and the age and health of
participants (likely differences in immunogenicity and suscepti-
bility to disease).
Another layer of complexity is the differences in antigen con-
tent, with the 23-valent vaccine containing a reduced amount of
purified capsular polysaccharide for each included serotype (25
µg compared to 50 µg for the lower-valency vaccines). Although
comparative studies showed similar antibody response with the
reduced antigen content, these were conducted using now dated
methods for antibody measurement. This aspect should be con-
sidered when interpreting the results of this meta-analysis.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This meta-analysis supports the use of pneumococcal polysac-
charide vaccine to prevent IPD in adults, particularly otherwise
healthy adults, in developed and developing country settings. The
evidence from our meta-analysis of RCTs does not support the
routine use of pneumococcal polysaccharide vaccine to prevent
all-cause pneumonia or mortality.
Implications for research
Given the effectiveness of the vaccine in protecting individuals
against IPD, commencing new RCTs in populations at risk where
vaccine effectiveness and disease burden is known would face eth-
ical difficulties, however, the 23-valent PPV may have a place as a
control treatment in RCTs of conjugate or potential protein vac-
cine candidates, which this review does not consider.
We have highlighted the potential differences in vaccine effective-
ness across population groups, where evidence of protective effi-
cacy from RCTs is less clear with respect to adults with chronic
illness. Given adults with chronic illness are the same population
who are targeted for vaccination, further trials assessing VE against
IPD amongst those with chronic disease appear warranted. How-
ever, such trials would need to be large given that this meta-analy-
sis of five pooled studies remained underpowered against the rare
event of IPD (2/1619 participants in the control group had the
outcome of interest).
We recommend the next update of this review to include adults
with chronic illness (including HIV) in both low and high income
countries in a population subgroup analysis.
Questions for future research that are not covered in this review
include the following. What is the interaction with previous PCV
vaccination? What is the effectiveness of PPV revaccination and
what is the length of protection? What is the effect of PPV on
nasopharyngeal carriage?
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Alfageme 2006
Methods Randomised controlled trial
Participants Participants diagnosed with chronic obstructive airways disease by spirometry at the University Hospital
of Valme, Spain (n = 600). Participants excluded if received previous pneumococcal vaccination, pregnant,
immunosuppressed, in dialysis, HIV+, asplenia
Interventions 23-valent PPV (n = 300), or no vaccine (n = 300). The study ran from 1999 to 2004 and follow up was
6 monthly, up to three years
Outcomes A1. Invasive pneumococcal disease
A2. Pneumonia (all causes)
A5. Definitive pneumococcal pneumonia
A7. Presumptive pneumococcal pneumonia
Notes Case ascertainment: Participant to contact doctor if temperature greater than 38 C
Primary outcome was time to first episode of CAP
Patients assigned vaccine/ no vaccine from a computer generated random number sequence. No reference
to blinding
No reference to sample size calculation
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Austrian 1976a
Methods Randomised controlled trial
Participants Young adult male miners in South Africa
Interventions 6-valent PPV first year, 13-valent second year, or Group A meningococcal vaccine or saline placebo. Total
participants across three studies n = 12,000
Outcomes A2. Pneumonia (all causes)
A4. Invasive pneumococcal disease (vaccine type)
Notes Follow up for 2 years
Participants assigned vaccine/control from table of random numbers
3 trials conducted, and data combined where relevant. Data for outcome 2 and 4 confirmed by corre-
spondence with author (from the previous version of this review). Not able to include outcome 1 (IPD)
as data not able to be extracted from figure 6 with certainty
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Austrian 1976a (Continued)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? No C - Inadequate
Austrian 1980a
Methods Randomised controlled trial
Participants Adult inpatients, Dorothea Dix Mental Hospital, USA
Interventions 6-valent PPV (n = 607), or saline placebo (n = 693)
Outcomes A2. Pneumonia (all causes)
A3. Mortality (all causes)
A9. Mortality due to pneumonia
Notes Follow up continued for 3 years (average 2.2 years)
Participants randomly assigned ’in double-blind fashion’, method not specified
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Austrian 1980b
Methods Randomised controlled trial
Participants Adults, Kaiser Permanente Health Plan, USA
Interventions 12-valent PPV (n = 6782) or saline placebo (n = 6818)
Outcomes A1. Invasive pneumococcal disease
A2. Pneumonia (all causes)
A3. Mortality (all causes)
A5. Definitive pneumococcal pneumonia
A6. Definitive pneumococcal pneumonia (vaccine type)
A9. Mortality due to pneumonia
Notes Average follow up 2.5 years
Participants randomly allocated by colour codes
Risk of bias
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Austrian 1980b (Continued)
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Benin 2003
Methods Matched case control study
Participants Navajo adults with IPD aged 18 and over with medical risk factor or above 65 years
Interventions 108 IPD case patients recruited in 1996 or 1997
330 control patients without prior IPD or pneumonia
23vPPV
Outcomes B1. Invasive pneumococcal disease
B2. Vaccine type invasive pneumococcal disease
Notes Matched 1: up to 7 according to age, sex, chronic medical condition (duration, number of conditions
and severity)
Cases more likely to have underlying disease and multiple underlying disease conditions (P = 0.0002).
Cases may have had prior IPD and controls excluded if prior IPD or pneumonia in previous 10 years
Likely bias against vaccine effectiveness
AIDS patients not excluded
Vaccinated defined as receiving any prior dose (23vPPV)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear D - Not used
Davis 1987
Methods Double blind randomised controlled trial
Participants Adults with chronic obstructive pulmonary disease, recruited from chest clinics in New York, USA
Participants excluded if malignant neoplasms, sickle cell disease, severe renal failure, hepatic impairment
Interventions 14-valent PPV (n = 50) administered subcutaneously (2 brands used), or saline placebo (n = 53)
Outcomes A1. Invasive pneumococcal disease
A2. Pneumonia (all causes)
A3. Mortality (all causes)
A5. Definitive pneumococcal pneumonia
A7. Presumptive pneumococcal pneumonia
A9. Mortality due to pneumonia
A10. Mortality due to pneumococcal infection
23Vaccines for preventing pneumococcal infection in adults (Review)
Copyright © 2008 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Davis 1987 (Continued)
Notes Average follow up 32 months
Groups appear similar apart from higher proportion of vaccinees currently smoking (53% compared
to 33%). More placebo participants had prior pneumonia and pneumococcal pneumonia (14 and 8
compared to 10 and 5)
Random allocated by table of random numbers
Risk of bias
Item Authors’ judgement Description
Allocation concealment? No C - Inadequate
Dominguez 2005
Methods Retrospective, matched case control study
Participants Cases hospitalised with invasive pneumococcal disease aged >= 65 years, conducted in Spain
Controls, 2 hospital, 1 outpatient control per case
Interventions 149 cases, 447 controls
23vPPV
Outcomes B1. Invasive pneumococcal disease (immunocompetent and immunocompetent elderly)
Notes Matched 3:1 according to age, date of hospitalisation, medical condition, and most important risk factor.
The outpatient control was also matched by risk conditional profile of case
33 case patients (18%) and 59 control patients were excluded as vaccination status was not able to be
determined
Cases were more likely to have longer mean hospital length of stay and death during hospitalisation
Considered vaccinated (23vPPV) from 14 days following administration
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear D - Not used
Gaillat 1985
Methods Randomised controlled trial
Participants Older adults living in hospices and retirement homes in France aged between 55 and 85 years.
Participants excluded if considered very high risk (>85 years with major visceral defect/ or 2 minor,
bedridden or immunocompromised)
Interventions 14-valent PPV (n = 937) administered subcutaneously, or influenza vaccine (n = 749)
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Gaillat 1985 (Continued)
Outcomes A1. Invasive pneumococcal disease
A2. Pneumonia (all causes)
A3. Mortality (all causes)
A5. Definitive pneumococcal pneumonia
Notes Followed up for 2 years
Case notification to researchers by pre-paid cards then researcher conducted follow up visits
Randomised by residential home according to proportion of high-risk patients in each facility
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Jackson 2003
Methods Retrospective cohort study
Participants Cohort of older adults aged 65 years and above, enrolled in a Group Health Cooperative in Washington
State
Interventions 47,365 people in cohort - study period March 1998 until February 2001
23vPPV
Outcomes B1. Invasive pneumococcal disease (immunocompetent and immunocompetent elderly)
Notes Followed up until death, dis-enrollment from HMO or end of study (maximum 3 years)
Model adjusted for age, sex, Nursing Home residence, influenza vaccination, smoking, chronic illness,
previous hospitalisation for pneumonia in last 12 months, number of outpatient visits. Follow up until
death, dis enrolled from HMO or end of study (3 years)
Considered vaccinated from 14 days following administration
Confirmation IPD confirmed by sterile site culture by personal communication with author
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear D - Not used
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Kaufman 1947
Methods Randomised controlled trial
Participants Patients of New York City Home, USA, aged above 40 years
Interventions 2-valent PPV given from 1937 to 1938 and 3-valent PPV given later types 1939 to 1942 (n = 5750), or
no intervention (n = 5153)
Outcomes A1. Invasive pneumococcal disease
A2. Pneumonia (all causes)
A3. Mortality (all causes)
A4. Invasive pneumococcal disease (vaccine type)
A5. Definitive pneumococcal pneumonia
A6. Definitive pneumococcal pneumonia (vaccine type)
A7. Presumptive pneumococcal pneumonia
A8. Presumptive pneumococcal pneumonia (vaccine type)
A9. Mortality due to pneumonia
Notes A continuation of Kaufman (1941)
Details regarding patient histories were taken, but not reported in paper (age comparison between groups
“was about the same, except that there were somewhat more persons in the oldest and somewhat less
persons in the youngest group among the controls”). Non pneumonia mortality was 91/1000 in the
vaccination group and 89/1000 in the control group
Average follow up for each group unclear (pneumonia incidence presented over 6 year period)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Klastersky 1986
Methods Randomised controlled trial
Participants Patients with bronchogenic carcinoma prior to receiving radiotherapy/ chemotherapy, aged 42 to 47,
Brussels, Belgium
Interventions 17-valent PPV (n = 26) administered subcutaneously, or identically packaged saline placebo (n = 21)
Outcomes A1. Invasive pneumococcal disease
A2. Pneumonia (all causes)
A3. Mortality (all causes)
A5. Definitive pneumococcal pneumonia
A7. Presumptive pneumococcal pneumonia
A9. Mortality due to pneumonia
A10. Mortality due to pneumococcal infection
Notes 3 participants lost to follow up (no details of which group). Length of follow up unclear
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Klastersky 1986 (Continued)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Koivula 1997
Methods Randomised controlled trial
Participants Older adults residing in town in eastern Finland, aged 60 years or above
Interventions 14-valent PPV and influenza vaccine (n = 1364), or influenza vaccine alone (n = 1473)
Outcomes A3. Mortality (all causes)
Notes Followed up for 3 years; 1983 to 1985. Randomisation appears to have occured prior to consent to
participate. Following randomisation, participants with high risk medical conditions also received annual
influenza vaccination
Unable to include all cause pneumonia as not all pneumonia radiological typical (appears to include
radiological uncertain)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? No C - Inadequate
Leech 1987
Methods Double blind randomised controlled trial
Participants Participants aged 40 to 89 years, with chronic obstructive lung disease (with FEV1 < 1.5L), recruited from
OPD at Montreal Chest hospital, Canada between January and June 1981
Interventions 14-valent PPV (n = 92) or saline placebo (n = 97), both groups were given influenza vaccine at the same
time and annually thereafter
Outcomes A1. Invasive pneumococcal disease
A3. Mortality (all causes)
A5. Definitive pneumococcal pneumonia
Notes Potential participants stratified by age, FEV and sex, then randomised
Follow up for two years at six monthly intervals
23 participants lost to follow up (which group is unclear)
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Leech 1987 (Continued)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Ortqvist 1998
Methods Double blind randomised controlled trial
Participants Non-immunocompromised adults aged 50 to 85 years who had been inpatients for community acquired
pneumonia in Sweden. Potential participants excluded if assumed poor compliance, previous receipt of
PPV, allergy to PPV or immunocompromised
Interventions 23-valent PPV (n = 339) administered intramuscularly (subcutaneous for patients on anticoagulant ther-
apy), or saline placebo (352)
Outcomes A1. Invasive pneumococcal disease
A2. Pneumonia (all causes)
A3. Mortality (all causes)
A4. Invasive pneumococcal disease (vaccine type)
A5. Definitive pneumococcal pneumonia
A6. Definitive pneumococcal pneumonia (vaccine type)
A7. Presumptive pneumococcal pneumonia
A8. Presumptive pneumococcal pneumonia (vaccine type)
A9. Mortality due to pneumonia
Notes Average follow up 2.5 years
Case ascertainment: participant to contact doctor if temperature above 38Cor cause to suspect pneumonia
recurrence. 1 participant withdrawn (n = 2, as randomised twice)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Riley 1977
Methods Double blind randomised controlled trial
Participants Adults from Tari in Papua New Guinea Highlands
Interventions 14-valent PPV (n = 5946), or saline placebo (6012). Surveillance subset of 2713 vaccinees, 2660 controls
for disease outcomes
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Riley 1977 (Continued)
Outcomes A1. Invasive pneumococcal disease
A2. Pneumonia (all causes)
A3. Mortality (all causes)
A4. Invasive pneumococcal disease (vaccine type)
A5. Definitive pneumococcal pneumonia
A6. Definitive pneumococcal pneumonia (vaccine type)
Notes Follow up 3 years for mortality and 16 months morbidity
540 records lost during transport, unclear which group, report likely equal numbers
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Shapiro 1984
Methods Matched case control study
Participants Adults aged 18 years and above with indication for vaccination or above 65 years (n = 180)
Interventions Cases (n = 90) hospitalised with IPD from 1978 to 1982 (no previous pneumococcal disease)
Controls (n = 90) selected from roster of hospitalised patients with no previous episode of pneumonia
14-valent PPV
Outcomes B1. Invasive pneumococcal disease (immunocompetent and immunocompetent elderly)
Notes Matched 1:1 according to age, date of hospitalisation, condition identified and vaccination indication
(duration, severity and number of illnesses)
Vaccination history reviewed from 1978 onwards
Vaccinated defined as receiving dose at least 2 weeks prior to selected hospitalisation (14vPPV)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear D - Not used
Shapiro 1991
Methods Matched case control study
Participants Adults aged 18 years and above with indication for vaccination or above 65 years (n = 2108)
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Shapiro 1991 (Continued)
Interventions Cases (n = 1054) hospitalised with IPD from 1984 to 1990 (no previous pneumococcal disease) and
pneumococcal isolate serotyped
Controls (n =1054) selected from roster of hospitalised patients with no previous episode of IPD during
the study period
Both 14-valent and 23-valent PPV
Outcomes B1. Invasive pneumococcal disease (immunocompetent)
B2. Vaccine type invasive pneumococcal disease (immunocompetent and immunocompetent elderly)
Notes Matched 1:1 according to age, date and site of hospitalisation, condition of vaccination indication (dura-
tion, severity and number of illnesses)
Less cases were white (862/921) and had a private physician (829/903). More cases were residents and
chronic care facility (181/ 117) and died during hospitalisation. Likely bias against vaccine effectiveness
Analysis according to indirect cohort methodwas conducted in a subgroup analysis of cases with a serotype
contained in the 14 valent vaccine compared to non23valent or 14 valent serotypes (23 valent non 14
valent serotype cases excluded)
Vaccinated defined as receiving dose at least 2 weeks prior to selected hospitalisation
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear D - Not used
Simberkoff 1986
Methods Double blind randomised controlled trial
Participants High risk ambulatory patients 55 years and above, referred from clinics, in the USA (with chronic renal,
hepatic, cardiac or pulmonary disease, alcoholism or diabetes)
Excluded if previous receipt of PPV, multiple myeloma, lymphoma or malignant disease, immunosup-
pressive treatment, history of splenectomy or functional asplenia
Interventions 14 valent PPV (n = 1175) administered subcutaneously, or saline placebo (1179)
Outcomes A1. Invasive pneumococcal disease
A2. Pneumonia (all causes)
A3. Mortality (all causes)
A4. Invasive pneumococcal disease (vaccine type)
A5. Definitive pneumococcal pneumonia
A7. Presumptive pneumococcal pneumonia
A8. Presumptive pneumococcal pneumonia (vaccine type)
A9. Mortality due to pneumonia
A10. Mortality due to pneumococcal infection
Notes Mean follow up period 2.9 years
More vaccinees had prior pneumococcal disease compared to placebo recipients (48 and 30 respectively,
p = 0.035)
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Simberkoff 1986 (Continued)
Additional low risk patients (n = 59) included for antibody response only
Loss to follow up not reported (statement in text satisfactory)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Sims 1988
Methods Matched case control
Participants Immunocompetent older adults aged 55 years and above
Interventions Cases (n = 122) IPD cases from Jan 1980 to July 1986
Controls (n = 244) consecutive hospital admissions
Vaccine valency not specified
Outcomes B1. Invasive pneumococcal disease (immunocompetent and immunocompetent elderly)
Notes Matched 2:1 according to hospital, admission date, comorbid conditions (number and severity)
Sample size based on VE at 50%, power 0.80, error 0.05 (one tailed) and 20% vaccination coverage in
controls requires 164 cases and 328 controls
Controls excluded if they had radiographically proven pneumonia during the study period
Vaccinated definition (time since dose) not specified
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear D - Not used
Smit 1977a
Methods Randomised controlled trial
Participants Young adult gold miners in South Africa (recruited within one day of arrival)
Interventions 6-valent PPV (n = 983), or meningococcal group A vaccine (n = 1051), or saline (n = 985). Total control
n = 2036
Outcomes A2. Pneumonia (all causes)
A7. Presumptive pneumococcal pneumonia
A8. Presumptive pneumococcal pneumonia (vaccine type)
31Vaccines for preventing pneumococcal infection in adults (Review)
Copyright © 2008 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Smit 1977a (Continued)
Notes Mean length of follow up not stated
Recruited between February 1973 to June 1974, with follow-up until May 1975
Maximum duration of follow up 2.3 years
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Smit 1977b
Methods Randomised controlled trial
Participants Young adult gold miners in South Africa (recruited within one day of arrival)
Interventions 12-valent PPV (n = 540), or meningococcal types A and C vaccine (n = 585); saline (n = 550). Total
control = 1135
Outcomes A2. Pneumonia (all causes)
A7. Presumptive pneumococcal pneumonia
A8. Presumptive pneumococcal pneumonia (vaccine type)
Notes Mean length of follow up not stated
Recruited between July 1974 to January 1976, with follow up until February 1976
Maximum duration of follow up 1.6 years
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Vila-Corcoles 2006
Methods Prospective cohort study
Participants Community dwelling older adults aged 65 years and above, assigned to primary health care centres
Interventions 11,241 members of the cohort. Study period from January 2002 until April 2005
23vPPV
Outcomes B1. Invasive pneumococcal disease (immunocompetent and immunocompetent elderly)
B2. Vaccine type invasive pneumococcal disease (immunocompetent and immunocompetent elderly)
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Vila-Corcoles 2006 (Continued)
Notes Cohort observed until study completion or first occurance of each outcome (maximum 3 years, 4 months)
IPD incidence of study participants 0.64/1000 person years
Model adjusted for age, sex, number of outpatient visits, history of hospitalisation for pneumonia in
previous 24 months, influenza vaccination status, underlying medical conditions, current smoking status
and immunocompromised status. Vaccination was a time variable factor; considered vaccinated from 14
days following administration
Results for IPD by vaccine type only serotypes provided by personal communication with first author
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear D - Not used
PPV: pneumococcal polysaccharide vaccine
IPD: invasive pneumococcal disease
CAP: community acquired pneumonia
OPD: Outpatient department
FEV: Forced expiratory volume
VE: Vaccine efficacy
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ammann 1977 Outcome was changes in antibody titres
Ansaldi 2005 Observational study with non IPD outcome
Austrian 1976b No useable data due to inadequate reporting
Bentley 1981 Cohort study, results not controlled for confounding factors
Bolan 1986 Data are included in a subsequent report : Butler 1993
Brieman 2000 HIV positive participants
Broome 1980 Data are included in a subsequent report: Butler 1993
Butler 1993 Indirect cohort study (no control of confounding factors)
Chiba 2004 All outcomes defined by ICD codes
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(Continued)
Chintu 1983 Non-randomised clinical trial, case series only
Christensen 2001 Only early interim results are available
Christenson 2004 Cases of IPD identified by ICD codes. No adjustment for confounding factors
Douglas 1984 Trial measures efficacy of vaccine in children
Douglas 1986 Trial measures efficacy of vaccine in children
Dworkin 2001 Cohort study in HIV positive participants
Farr 1995 Age of participants from 2 years. No subgroup analysis for adults able to be included
Fletcher 1997 Outcome was changes in antibody titres
Forrester 1987 This study was designed as a case control study, but VE estimate given according to indirect cohort method. No
sample size calculation, not powered for this analysis. No control of confounding factors in this methodology
Franzen 2000 Observational study with non-IPD outcome
Hedlund 2003 Interim results of Christenson 2004. Methodological issues of case identification by ICD codes and no control
for confounding factors
Honkanen 1999 Not able to be includedwithRCT’s as this trial is not randomised (initially year of birth allocation, but participants
also able to choose group). Not able to be included in observational review due to lack of control of confounding
factors
Karma 1985 Trial measures efficacy of vaccine in children
Kaufman 1941 All results included in second report (Kaufman 1947)
Lindenburg 2001 Observational study with non-IPD outcome
MacLeod 1945 No usable data due to inadequate reporting
MMWR 2001 Not all cases confirmed as IPD (7 of 9 confirmed by blood culture)
Mykietiuk 2006 Case series, no comparison group
Nichol 1999 Cohort study, primary outcome pneumonia defined by ICD codes
Rosen 1983 Trial measures efficacy of vaccine in children
Wagner 2003 Observational study with non-IPD outcome
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D A T A A N D A N A L Y S E S
Comparison 1. RCTs of vaccination versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Invasive pneumococcal disease 10 Odds Ratio (M-H, Random, 95% CI) Subtotals only
1.1 All studies 10 35483 Odds Ratio (M-H, Random, 95% CI) 0.26 [0.15, 0.46]
1.2 i) Adults in low income
countries
1 5373 Odds Ratio (M-H, Random, 95% CI) 0.14 [0.03, 0.61]
1.3 ii) Adults in high income
countries with chronic illness
5 3230 Odds Ratio (M-H, Random, 95% CI) 1.56 [0.35, 6.94]
1.4 iii) Adults in high income
countries
4 26880 Odds Ratio (M-H, Random, 95% CI) 0.20 [0.10, 0.41]
2 Pneumonia, all causes 13 Odds Ratio (M-H, Random, 95% CI) Subtotals only
2.1 All studies 13 45783 Odds Ratio (M-H, Random, 95% CI) 0.71 [0.52, 0.97]
2.2 i) Adults in low income
countries
4 14562 Odds Ratio (M-H, Random, 95% CI) 0.54 [0.43, 0.67]
2.3 ii) Adults in high income
countries with chronic illness
4 3041 Odds Ratio (M-H, Random, 95% CI) 0.97 [0.65, 1.46]
2.4 iii) Adults in high income
countries
5 28180 Odds Ratio (M-H, Random, 95% CI) 0.74 [0.43, 1.27]
3 Mortality, all causes 11 Odds Ratio (M-H, Random, 95% CI) Subtotals only
3.1 All studies 11 45609 Odds Ratio (M-H, Random, 95% CI) 0.87 [0.69, 1.10]
3.2 i) Adults in low income
countries
1 11958 Odds Ratio (M-H, Random, 95% CI) 0.79 [0.62, 0.99]
3.3 ii) Adults in high income
countries with chronic illness
4 2634 Odds Ratio (M-H, Random, 95% CI) 1.04 [0.66, 1.64]
3.4 iii) Older adults in high
income countries
6 31017 Odds Ratio (M-H, Random, 95% CI) 0.84 [0.61, 1.17]
4 Invasive pneumococcal disease
(vaccine types only)
5 31223 Odds Ratio (M-H, Random, 95% CI) 0.18 [0.10, 0.31]
5 Definitive pneumococcal
pneumonia
10 35483 Odds Ratio (M-H, Random, 95% CI) 0.26 [0.15, 0.46]
5.1 All studies 10 35483 Odds Ratio (M-H, Random, 95% CI) 0.26 [0.15, 0.46]
6 Definitive pneumococcal
pneumonia (vaccine types only)
4 30561 Odds Ratio (M-H, Random, 95% CI) 0.13 [0.05, 0.38]
7 Presumptive pneumococcal
pneumonia
8 19329 Odds Ratio (M-H, Random, 95% CI) 0.47 [0.23, 0.99]
8 Presumptive pneumococcal
pneumonia (vaccine types only)
5 18568 Odds Ratio (M-H, Random, 95% CI) 0.27 [0.08, 0.87]
9 Mortality due to pneumonia 7 28939 Odds Ratio (M-H, Random, 95% CI) 0.75 [0.39, 1.43]
10 Mortality due to pneumococcal
infection
3 2445 Odds Ratio (M-H, Random, 95% CI) 2.51 [0.45, 14.13]
11 Pneumococcal nasopharyngeal
colonisation
0 0 Odds Ratio (M-H, Random, 95% CI) Not estimable
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Comparison 2. Non-randomised studies
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Invasive pneumococcal disease
(all types)
7 OR (Random, 95% CI) Subtotals only
1.1 All studies 7 OR (Random, 95% CI) 0.48 [0.37, 0.61]
1.2 Immunocompetent 6 OR (Random, 95% CI) 0.41 [0.32, 0.52]
1.3 Immunocompetent older
adults
5 OR (Random, 95% CI) 0.32 [0.22, 0.47]
1.4 Cohort studies 2 OR (Random, 95% CI) 0.57 [0.36, 0.89]
1.5 Case control studies 4 OR (Random, 95% CI) 0.47 [0.32, 0.68]
2 Invasive pneumococcal disease
(vaccine type)
3 OR (Random, 95% CI) Subtotals only
2.1 All studies 3 OR (Random, 95% CI) 0.45 [0.38, 0.54]
2.2 Immunocompetent 2 OR (Random, 95% CI) 0.40 [0.29, 0.54]
2.3 Immunocompetent older
adults
1 OR (Random, 95% CI) 0.66 [0.14, 3.03]
Analysis 1.1. Comparison 1 RCTs of vaccination versus placebo, Outcome 1 Invasive pneumococcal disease.
Review: Vaccines for preventing pneumococcal infection in adults
Comparison: 1 RCTs of vaccination versus placebo
Outcome: 1 Invasive pneumococcal disease
Study or subgroup Vaccine Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 All studies
Alfageme 2006 0/298 0/298 Not estimable
Austrian 1980b 0/6782 4/6818 3.9 % 0.11 [ 0.01, 2.07 ]
Davis 1987 1/50 0/53 3.2 % 3.24 [ 0.13, 81.47 ]
Gaillat 1985 0/937 1/749 3.2 % 0.27 [ 0.01, 6.54 ]
Kaufman 1947 8/5750 34/5153 55.8 % 0.21 [ 0.10, 0.45 ]
Klastersky 1986 1/26 1/21 4.1 % 0.80 [ 0.05, 13.60 ]
Leech 1987 1/92 0/97 3.2 % 3.20 [ 0.13, 79.47 ]
Ortqvist 1998 1/339 5/352 7.2 % 0.21 [ 0.02, 1.77 ]
0.01 0.1 1 10 100
Favours vaccine Favours control
(Continued . . . )
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(. . . Continued)
Study or subgroup Vaccine Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Riley 1977 2/2713 14/2660 15.1 % 0.14 [ 0.03, 0.61 ]
Simberkoff 1986 1/1145 1/1150 4.3 % 1.00 [ 0.06, 16.08 ]
Subtotal (95% CI) 18132 17351 100.0 % 0.26 [ 0.15, 0.46 ]
Total events: 15 (Vaccine), 60 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 7.56, df = 8 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 4.57 (P < 0.00001)
2 i) Adults in low income countries
Riley 1977 2/2713 14/2660 100.0 % 0.14 [ 0.03, 0.61 ]
Subtotal (95% CI) 2713 2660 100.0 % 0.14 [ 0.03, 0.61 ]
Total events: 2 (Vaccine), 14 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.60 (P = 0.0092)
3 ii) Adults in high income countries with chronic illness
Alfageme 2006 0/298 0/298 Not estimable
Davis 1987 1/50 0/53 21.5 % 3.24 [ 0.13, 81.47 ]
Klastersky 1986 1/26 1/21 27.8 % 0.80 [ 0.05, 13.60 ]
Leech 1987 1/92 0/97 21.6 % 3.20 [ 0.13, 79.47 ]
Simberkoff 1986 1/1145 1/1150 29.0 % 1.00 [ 0.06, 16.08 ]
Subtotal (95% CI) 1611 1619 100.0 % 1.56 [ 0.35, 6.94 ]
Total events: 4 (Vaccine), 2 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.70, df = 3 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.58 (P = 0.56)
4 iii) Adults in high income countries
Austrian 1980b 0/6782 4/6818 5.5 % 0.11 [ 0.01, 2.07 ]
Gaillat 1985 0/937 1/749 4.6 % 0.27 [ 0.01, 6.54 ]
Kaufman 1947 8/5750 34/5153 79.6 % 0.21 [ 0.10, 0.45 ]
Ortqvist 1998 1/339 5/352 10.2 % 0.21 [ 0.02, 1.77 ]
Subtotal (95% CI) 13808 13072 100.0 % 0.20 [ 0.10, 0.41 ]
Total events: 9 (Vaccine), 44 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.20, df = 3 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 4.52 (P < 0.00001)
0.01 0.1 1 10 100
Favours vaccine Favours control
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Analysis 1.2. Comparison 1 RCTs of vaccination versus placebo, Outcome 2 Pneumonia, all causes.
Review: Vaccines for preventing pneumococcal infection in adults
Comparison: 1 RCTs of vaccination versus placebo
Outcome: 2 Pneumonia, all causes
Study or subgroup Vaccine Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 All studies
Alfageme 2006 37/298 39/298 8.4 % 0.94 [ 0.58, 1.52 ]
Austrian 1976a 85/1493 359/3002 10.1 % 0.44 [ 0.35, 0.57 ]
Austrian 1980a 154/607 144/693 10.1 % 1.30 [ 1.00, 1.68 ]
Austrian 1980b 268/6782 274/6818 10.5 % 0.98 [ 0.83, 1.17 ]
Davis 1987 3/50 7/53 3.1 % 0.42 [ 0.10, 1.72 ]
Gaillat 1985 3/937 12/749 3.6 % 0.20 [ 0.06, 0.70 ]
Kaufman 1947 99/5750 227/5153 10.2 % 0.38 [ 0.30, 0.48 ]
Klastersky 1986 2/26 4/21 2.1 % 0.35 [ 0.06, 2.16 ]
Ortqvist 1998 63/339 57/352 9.1 % 1.18 [ 0.80, 1.75 ]
Riley 1977 27/2713 40/2660 8.4 % 0.66 [ 0.40, 1.08 ]
Simberkoff 1986 48/1145 38/1150 8.8 % 1.28 [ 0.83, 1.98 ]
Smit 1977a 37/983 121/2036 9.3 % 0.62 [ 0.42, 0.90 ]
Smit 1977b 9/540 28/1135 6.3 % 0.67 [ 0.31, 1.43 ]
Subtotal (95% CI) 21663 24120 100.0 % 0.71 [ 0.52, 0.97 ]
Total events: 835 (Vaccine), 1350 (Control)
Heterogeneity: Tau2 = 0.23; Chi2 = 94.15, df = 12 (P<0.00001); I2 =87%
Test for overall effect: Z = 2.19 (P = 0.029)
2 i) Adults in low income countries
Austrian 1976a 85/1493 359/3002 29.8 % 0.44 [ 0.35, 0.57 ]
Riley 1977 27/2713 40/2660 24.5 % 0.66 [ 0.40, 1.08 ]
Smit 1977a 37/983 121/2036 27.2 % 0.62 [ 0.42, 0.90 ]
Smit 1977b 9/540 28/1135 18.5 % 0.67 [ 0.31, 1.43 ]
Subtotal (95% CI) 5729 8833 100.0 % 0.54 [ 0.43, 0.67 ]
Total events: 158 (Vaccine), 548 (Control)
Heterogeneity: Tau2 = 0.01; Chi2 = 3.72, df = 3 (P = 0.29); I2 =19%
Test for overall effect: Z = 5.54 (P < 0.00001)
3 ii) Adults in high income countries with chronic illness
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(. . . Continued)
Study or subgroup Vaccine Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Alfageme 2006 37/298 39/298 37.6 % 0.94 [ 0.58, 1.52 ]
Davis 1987 3/50 7/53 13.7 % 0.42 [ 0.10, 1.72 ]
Klastersky 1986 2/26 4/21 9.4 % 0.35 [ 0.06, 2.16 ]
Simberkoff 1986 48/1145 38/1150 39.3 % 1.28 [ 0.83, 1.98 ]
Subtotal (95% CI) 1519 1522 100.0 % 0.97 [ 0.65, 1.46 ]
Total events: 90 (Vaccine), 88 (Control)
Heterogeneity: Tau2 = 0.04; Chi2 = 4.00, df = 3 (P = 0.26); I2 =25%
Test for overall effect: Z = 0.13 (P = 0.90)
4 iii) Adults in high income countries
Austrian 1980a 154/607 144/693 23.1 % 1.30 [ 1.00, 1.68 ]
Austrian 1980b 268/6782 274/6818 24.2 % 0.98 [ 0.83, 1.17 ]
Gaillat 1985 3/937 12/749 8.2 % 0.20 [ 0.06, 0.70 ]
Kaufman 1947 99/5750 227/5153 23.4 % 0.38 [ 0.30, 0.48 ]
Ortqvist 1998 63/339 57/352 21.0 % 1.18 [ 0.80, 1.75 ]
Subtotal (95% CI) 14415 13765 100.0 % 0.74 [ 0.43, 1.27 ]
Total events: 587 (Vaccine), 714 (Control)
Heterogeneity: Tau2 = 0.31; Chi2 = 64.18, df = 4 (P<0.00001); I2 =94%
Test for overall effect: Z = 1.08 (P = 0.28)
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Analysis 1.3. Comparison 1 RCTs of vaccination versus placebo, Outcome 3 Mortality, all causes.
Review: Vaccines for preventing pneumococcal infection in adults
Comparison: 1 RCTs of vaccination versus placebo
Outcome: 3 Mortality, all causes
Study or subgroup Vaccine Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 All studies
Austrian 1980a 35/607 44/693 9.2 % 0.90 [ 0.57, 1.43 ]
Austrian 1980b 45/6782 47/6818 10.0 % 0.96 [ 0.64, 1.45 ]
Davis 1987 14/50 13/53 4.5 % 1.20 [ 0.50, 2.88 ]
Gaillat 1985 232/937 175/749 13.2 % 1.08 [ 0.86, 1.35 ]
Kaufman 1947 40/5750 98/5153 10.7 % 0.36 [ 0.25, 0.52 ]
Klastersky 1986 2/26 4/21 1.4 % 0.35 [ 0.06, 2.16 ]
Koivula 1997 152/1364 166/1473 13.1 % 0.99 [ 0.78, 1.25 ]
Leech 1987 6/92 11/97 3.5 % 0.55 [ 0.19, 1.54 ]
Ortqvist 1998 29/339 28/352 8.0 % 1.08 [ 0.63, 1.86 ]
Riley 1977 133/5946 170/6012 13.1 % 0.79 [ 0.62, 0.99 ]
Simberkoff 1986 211/1145 171/1150 13.3 % 1.29 [ 1.04, 1.61 ]
Subtotal (95% CI) 23038 22571 100.0 % 0.87 [ 0.69, 1.10 ]
Total events: 899 (Vaccine), 927 (Control)
Heterogeneity: Tau2 = 0.09; Chi2 = 40.47, df = 10 (P = 0.00001); I2 =75%
Test for overall effect: Z = 1.15 (P = 0.25)
2 i) Adults in low income countries
Riley 1977 133/5946 170/6012 100.0 % 0.79 [ 0.62, 0.99 ]
Subtotal (95% CI) 5946 6012 100.0 % 0.79 [ 0.62, 0.99 ]
Total events: 133 (Vaccine), 170 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.05 (P = 0.040)
3 ii) Adults in high income countries with chronic illness
Davis 1987 14/50 13/53 19.8 % 1.20 [ 0.50, 2.88 ]
Klastersky 1986 2/26 4/21 6.0 % 0.35 [ 0.06, 2.16 ]
Leech 1987 6/92 11/97 15.5 % 0.55 [ 0.19, 1.54 ]
Simberkoff 1986 211/1145 171/1150 58.7 % 1.29 [ 1.04, 1.61 ]
Subtotal (95% CI) 1313 1321 100.0 % 1.04 [ 0.66, 1.64 ]
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(. . . Continued)
Study or subgroup Vaccine Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 233 (Vaccine), 199 (Control)
Heterogeneity: Tau2 = 0.08; Chi2 = 4.38, df = 3 (P = 0.22); I2 =31%
Test for overall effect: Z = 0.16 (P = 0.87)
4 iii) Older adults in high income countries
Austrian 1980a 35/607 44/693 14.4 % 0.90 [ 0.57, 1.43 ]
Austrian 1980b 45/6782 47/6818 15.6 % 0.96 [ 0.64, 1.45 ]
Gaillat 1985 232/937 175/749 20.6 % 1.08 [ 0.86, 1.35 ]
Kaufman 1947 40/5750 98/5153 16.7 % 0.36 [ 0.25, 0.52 ]
Koivula 1997 152/1364 166/1473 20.3 % 0.99 [ 0.78, 1.25 ]
Ortqvist 1998 29/339 28/352 12.4 % 1.08 [ 0.63, 1.86 ]
Subtotal (95% CI) 15779 15238 100.0 % 0.84 [ 0.61, 1.17 ]
Total events: 533 (Vaccine), 558 (Control)
Heterogeneity: Tau2 = 0.13; Chi2 = 27.11, df = 5 (P = 0.00005); I2 =82%
Test for overall effect: Z = 1.02 (P = 0.31)
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Analysis 1.4. Comparison 1 RCTs of vaccination versus placebo, Outcome 4 Invasive pneumococcal disease
(vaccine types only).
Review: Vaccines for preventing pneumococcal infection in adults
Comparison: 1 RCTs of vaccination versus placebo
Outcome: 4 Invasive pneumococcal disease (vaccine types only)
Study or subgroup Vaccine Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Austrian 1976a 10/3943 113/8024 72.1 % 0.18 [ 0.09, 0.34 ]
Kaufman 1947 0/5749 7/5148 3.7 % 0.06 [ 0.00, 1.04 ]
Ortqvist 1998 1/339 5/352 6.5 % 0.21 [ 0.02, 1.77 ]
Riley 1977 2/2713 14/2660 13.8 % 0.14 [ 0.03, 0.61 ]
Simberkoff 1986 1/1145 1/1150 3.9 % 1.00 [ 0.06, 16.08 ]
Total (95% CI) 13889 17334 100.0 % 0.18 [ 0.10, 0.31 ]
Total events: 14 (Vaccine), 140 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.19, df = 4 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 6.14 (P < 0.00001)
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Analysis 1.5. Comparison 1 RCTs of vaccination versus placebo, Outcome 5 Definitive pneumococcal
pneumonia.
Review: Vaccines for preventing pneumococcal infection in adults
Comparison: 1 RCTs of vaccination versus placebo
Outcome: 5 Definitive pneumococcal pneumonia
Study or subgroup Vaccine Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 All studies
Alfageme 2006 0/298 0/298 Not estimable
Austrian 1980b 0/6782 4/6818 3.9 % 0.11 [ 0.01, 2.07 ]
Davis 1987 1/50 0/53 3.2 % 3.24 [ 0.13, 81.47 ]
Gaillat 1985 0/937 1/749 3.2 % 0.27 [ 0.01, 6.54 ]
Kaufman 1947 8/5750 34/5153 55.8 % 0.21 [ 0.10, 0.45 ]
Klastersky 1986 1/26 1/21 4.1 % 0.80 [ 0.05, 13.60 ]
Leech 1987 1/92 0/97 3.2 % 3.20 [ 0.13, 79.47 ]
Ortqvist 1998 1/339 5/352 7.2 % 0.21 [ 0.02, 1.77 ]
Riley 1977 2/2713 14/2660 15.1 % 0.14 [ 0.03, 0.61 ]
Simberkoff 1986 1/1145 1/1150 4.3 % 1.00 [ 0.06, 16.08 ]
Total (95% CI) 18132 17351 100.0 % 0.26 [ 0.15, 0.46 ]
Total events: 15 (Vaccine), 60 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 7.56, df = 8 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 4.57 (P < 0.00001)
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Analysis 1.6. Comparison 1 RCTs of vaccination versus placebo, Outcome 6 Definitive pneumococcal
pneumonia (vaccine types only).
Review: Vaccines for preventing pneumococcal infection in adults
Comparison: 1 RCTs of vaccination versus placebo
Outcome: 6 Definitive pneumococcal pneumonia (vaccine types only)
Study or subgroup Vaccine Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Austrian 1980b 0/6782 4/6818 12.9 % 0.11 [ 0.01, 2.07 ]
Kaufman 1947 0/5749 7/5148 13.4 % 0.06 [ 0.00, 1.04 ]
Ortqvist 1998 1/339 5/352 23.7 % 0.21 [ 0.02, 1.77 ]
Riley 1977 2/2713 14/2660 50.0 % 0.14 [ 0.03, 0.61 ]
Total (95% CI) 15583 14978 100.0 % 0.13 [ 0.05, 0.38 ]
Total events: 3 (Vaccine), 30 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.49, df = 3 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 3.78 (P = 0.00016)
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Analysis 1.7. Comparison 1 RCTs of vaccination versus placebo, Outcome 7 Presumptive pneumococcal
pneumonia.
Review: Vaccines for preventing pneumococcal infection in adults
Comparison: 1 RCTs of vaccination versus placebo
Outcome: 7 Presumptive pneumococcal pneumonia
Study or subgroup Vaccine Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Alfageme 2006 0/298 5/298 4.9 % 0.09 [ 0.00, 1.62 ]
Davis 1987 2/50 0/53 4.5 % 5.52 [ 0.26, 117.76 ]
Kaufman 1947 34/5750 96/5153 19.8 % 0.31 [ 0.21, 0.46 ]
Klastersky 1986 2/26 4/21 9.2 % 0.35 [ 0.06, 2.16 ]
Ortqvist 1998 19/339 16/352 17.8 % 1.25 [ 0.63, 2.47 ]
Simberkoff 1986 19/1145 15/1150 17.8 % 1.28 [ 0.65, 2.53 ]
Smit 1977a 9/983 78/2036 17.7 % 0.23 [ 0.12, 0.46 ]
Smit 1977b 1/540 25/1135 8.2 % 0.08 [ 0.01, 0.61 ]
Total (95% CI) 9131 10198 100.0 % 0.47 [ 0.23, 0.99 ]
Total events: 86 (Vaccine), 239 (Control)
Heterogeneity: Tau2 = 0.66; Chi2 = 31.37, df = 7 (P = 0.00005); I2 =78%
Test for overall effect: Z = 2.00 (P = 0.045)
0.01 0.1 1 10 100
Favours vaccine Favours control
45Vaccines for preventing pneumococcal infection in adults (Review)
Copyright © 2008 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.8. Comparison 1 RCTs of vaccination versus placebo, Outcome 8 Presumptive pneumococcal
pneumonia (vaccine types only).
Review: Vaccines for preventing pneumococcal infection in adults
Comparison: 1 RCTs of vaccination versus placebo
Outcome: 8 Presumptive pneumococcal pneumonia (vaccine types only)
Study or subgroup Vaccine Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Kaufman 1947 1/5748 20/5140 16.8 % 0.04 [ 0.01, 0.33 ]
Ortqvist 1998 1/339 1/352 11.7 % 1.04 [ 0.06, 16.67 ]
Simberkoff 1986 7/1145 6/1150 25.4 % 1.17 [ 0.39, 3.50 ]
Smit 1977a 9/983 78/2036 29.1 % 0.23 [ 0.12, 0.46 ]
Smit 1977b 1/540 25/1135 16.9 % 0.08 [ 0.01, 0.61 ]
Total (95% CI) 8755 9813 100.0 % 0.27 [ 0.08, 0.87 ]
Total events: 19 (Vaccine), 130 (Control)
Heterogeneity: Tau2 = 1.15; Chi2 = 13.17, df = 4 (P = 0.01); I2 =70%
Test for overall effect: Z = 2.18 (P = 0.029)
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Analysis 1.9. Comparison 1 RCTs of vaccination versus placebo, Outcome 9 Mortality due to pneumonia.
Review: Vaccines for preventing pneumococcal infection in adults
Comparison: 1 RCTs of vaccination versus placebo
Outcome: 9 Mortality due to pneumonia
Study or subgroup Vaccine Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Austrian 1980a 23/607 30/693 19.9 % 0.87 [ 0.50, 1.52 ]
Austrian 1980b 36/6782 38/6818 20.9 % 0.95 [ 0.60, 1.50 ]
Davis 1987 2/50 4/53 8.7 % 0.51 [ 0.09, 2.92 ]
Kaufman 1947 31/5750 98/5153 21.4 % 0.28 [ 0.19, 0.42 ]
Klastersky 1986 1/26 1/21 4.3 % 0.80 [ 0.05, 13.60 ]
Ortqvist 1998 2/339 3/352 8.3 % 0.69 [ 0.11, 4.16 ]
Simberkoff 1986 16/1145 8/1150 16.6 % 2.02 [ 0.86, 4.75 ]
Total (95% CI) 14699 14240 100.0 % 0.75 [ 0.39, 1.43 ]
Total events: 111 (Vaccine), 182 (Control)
Heterogeneity: Tau2 = 0.47; Chi2 = 27.20, df = 6 (P = 0.00013); I2 =78%
Test for overall effect: Z = 0.88 (P = 0.38)
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Analysis 1.10. Comparison 1 RCTs of vaccination versus placebo, Outcome 10 Mortality due to
pneumococcal infection.
Review: Vaccines for preventing pneumococcal infection in adults
Comparison: 1 RCTs of vaccination versus placebo
Outcome: 10 Mortality due to pneumococcal infection
Study or subgroup Vaccine Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Davis 1987 1/50 0/53 28.8 % 3.24 [ 0.13, 81.47 ]
Klastersky 1986 1/26 1/21 37.2 % 0.80 [ 0.05, 13.60 ]
Simberkoff 1986 3/1145 0/1150 34.0 % 7.05 [ 0.36, 136.62 ]
Total (95% CI) 1221 1224 100.0 % 2.51 [ 0.45, 14.13 ]
Total events: 5 (Vaccine), 1 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.14, df = 2 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 1.04 (P = 0.30)
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Analysis 2.1. Comparison 2 Non-randomised studies, Outcome 1 Invasive pneumococcal disease (all types).
Review: Vaccines for preventing pneumococcal infection in adults
Comparison: 2 Non-randomised studies
Outcome: 1 Invasive pneumococcal disease (all types)
Study or subgroup log [OR] OR Weight OR
(SE) IV,Random,95% CI IV,Random,95% CI
1 All studies
Benin 2003 -0.3011 (0.2805) 13.3 % 0.74 [ 0.43, 1.28 ]
Dominguez 2005 -1.2039 (0.2652) 14.7 % 0.30 [ 0.18, 0.50 ]
Jackson 2003 -0.5798 (0.259) 15.2 % 0.56 [ 0.34, 0.93 ]
Shapiro 1984 -1.1086 (0.4752) 5.1 % 0.33 [ 0.13, 0.84 ]
Shapiro 1991 -0.6348 (0.1337) 39.1 % 0.53 [ 0.41, 0.69 ]
Sims 1988 -1.2039 (0.376) 7.9 % 0.30 [ 0.14, 0.63 ]
Vila-Corcoles 2006 -0.5108 (0.5037) 4.6 % 0.60 [ 0.22, 1.61 ]
Subtotal (95% CI) 100.0 % 0.48 [ 0.37, 0.61 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 8.75, df = 6 (P = 0.19); I2 =31%
Test for overall effect: Z = 5.78 (P < 0.00001)
2 Immunocompetent
Dominguez 2005 -1.4271 (0.3517) 8.1 % 0.24 [ 0.12, 0.48 ]
Jackson 2003 -1.0498 (0.4567) 5.0 % 0.35 [ 0.14, 0.86 ]
Shapiro 1984 -1.2039 (0.5994) 3.0 % 0.30 [ 0.09, 0.97 ]
Shapiro 1991 -0.755 (0.0432) 72.5 % 0.47 [ 0.43, 0.51 ]
Sims 1988 -1.2039 (0.376) 7.2 % 0.30 [ 0.14, 0.63 ]
Vila-Corcoles 2006 -0.5108 (0.5037) 4.2 % 0.60 [ 0.22, 1.61 ]
Subtotal (95% CI) 100.0 % 0.41 [ 0.32, 0.52 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 6.10, df = 5 (P = 0.30); I2 =18%
Test for overall effect: Z = 7.27 (P < 0.00001)
3 Immunocompetent older adults
Dominguez 2005 -1.4271 (0.3517) 29.5 % 0.24 [ 0.12, 0.48 ]
Jackson 2003 -1.0498 (0.4567) 18.3 % 0.35 [ 0.14, 0.86 ]
Shapiro 1984 -1.2039 (0.5994) 10.9 % 0.30 [ 0.09, 0.97 ]
Sims 1988 -1.2039 (0.376) 26.2 % 0.30 [ 0.14, 0.63 ]
Vila-Corcoles 2006 -0.5108 (0.5037) 15.2 % 0.60 [ 0.22, 1.61 ]
Subtotal (95% CI) 100.0 % 0.32 [ 0.22, 0.47 ]
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(. . . Continued)
Study or subgroup log [OR] OR Weight OR
(SE) IV,Random,95% CI IV,Random,95% CI
Heterogeneity: Tau2 = 0.0; Chi2 = 2.31, df = 4 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 5.90 (P < 0.00001)
4 Cohort studies
Jackson 2003 -0.5798 (0.259) 76.8 % 0.56 [ 0.34, 0.93 ]
Vila-Corcoles 2006 -0.5108 (0.5037) 23.2 % 0.60 [ 0.22, 1.61 ]
Subtotal (95% CI) 100.0 % 0.57 [ 0.36, 0.89 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 2.45 (P = 0.014)
5 Case control studies
Benin 2003 -0.3011 (0.2805) 18.5 % 0.74 [ 0.43, 1.28 ]
Dominguez 2005 -1.2039 (0.2652) 20.3 % 0.30 [ 0.18, 0.50 ]
Shapiro 1984 -1.1086 (0.4752) 7.1 % 0.33 [ 0.13, 0.84 ]
Shapiro 1991 -0.6348 (0.1337) 54.2 % 0.53 [ 0.41, 0.69 ]
Subtotal (95% CI) 100.0 % 0.47 [ 0.32, 0.68 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 6.61, df = 3 (P = 0.09); I2 =55%
Test for overall effect: Z = 3.94 (P = 0.000082)
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Analysis 2.2. Comparison 2 Non-randomised studies, Outcome 2 Invasive pneumococcal disease (vaccine
type).
Review: Vaccines for preventing pneumococcal infection in adults
Comparison: 2 Non-randomised studies
Outcome: 2 Invasive pneumococcal disease (vaccine type)
Study or subgroup log [OR] OR Weight OR
(SE) IV,Random,95% CI IV,Random,95% CI
1 All studies
Benin 2003 -0.478 (0.4184) 4.7 % 0.62 [ 0.27, 1.41 ]
Shapiro 1991 -0.8209 (0.0936) 93.9 % 0.44 [ 0.37, 0.53 ]
Vila-Corcoles 2006 -0.4155 (0.7776) 1.4 % 0.66 [ 0.14, 3.03 ]
Subtotal (95% CI) 100.0 % 0.45 [ 0.38, 0.54 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.89, df = 2 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 8.81 (P < 0.00001)
2 Immunocompetent
Shapiro 1991 -0.9416 (0.1595) 96.0 % 0.39 [ 0.29, 0.53 ]
Vila-Corcoles 2006 -0.4155 (0.7776) 4.0 % 0.66 [ 0.14, 3.03 ]
Subtotal (95% CI) 100.0 % 0.40 [ 0.29, 0.54 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.44, df = 1 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 5.89 (P < 0.00001)
3 Immunocompetent older adults
Vila-Corcoles 2006 -0.4155 (0.7776) 100.0 % 0.66 [ 0.14, 3.03 ]
Subtotal (95% CI) 100.0 % 0.66 [ 0.14, 3.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.53 (P = 0.59)
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A D D I T I O N A L T A B L E S
Table 1. Quality assessment of pneumococcal trials (after Jadad et al)
Study ID Ran-
domised
Sequence
ok
Double
blind
With-
drawals
Blinding
method
Random.
inapprop.
Dbl-blind
inapprop.
Total score
0-5
Alfageme
2006
1 1 1 3
Austrian
1976
1 1 2
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Table 1. Quality assessment of pneumococcal trials (after Jadad et al) (Continued)
Austrian
1980 (1)
1 1 1 1 1 5
Austrian
1980 (2)
1 1 1 1 1 5
Davis 1987 1 1 1 1 4
Gaillat 1985 1 1 2
Kauffman
1947
0
Klastersky
1986
1 1 1 1 4
Koivula
1997
1 1
Leech 1987 1 1 1 3
Ortqvist,
1998
1 1 1 1 1 5
Riley 1977 1 1 2
Simberkoff
1986
1 1 1 1 4
Smit 1977
(1)
1 1 2
Smit 1977
(2)
1 1 2
F E E D B A C K
Best systematic of 23-valent pneumococcal vaccine
Summary
Dear Authors,
The inclusion of non-controlled studies in the current systematic review is clearly a step forward. The case-control studies enables an
analysis of invasive pneumococcal disease that is not possible to do with the prospective studies that have been performed, due to lack of
power. However, there is also a well performed cohort study, adjusted for background factors, that showed the same preventive efficacy
against IPD (Jackson NEJMMAy 2003). Why was that not included? The search strategy stated that you included papers up to June
2003.
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For your information, there are some new data from the study that was published as an early report in Lancet 2001 by Christenson et
al. This, however, was published during the fall of 2003. (Hedlund J, Christenson B, Lundbergh P, Örtqvist Å. Effects of a large-scale
intervention with influenza and 23-valent pneumococcal vaccines in elderly people: a one-year follow-up. Vaccine 2003; 21: 3906-11).
Although we are still working with a “complete” background adjustment of the groups to minimise biases, the results of this paper was
sex and age adjusted. In addition, a comparison was made between influenza season and non-influenza. In that comparison it can be
seen that there was a significant prevention against both influenza, pneumonia and IPD during the influenza season in patients who
had received influenza and/or pneumococcal vaccine. During the non-influenza season, however, there was no difference concerning
influenza, whereas there was still a significant protection against pneumonia. For IPD the RR was the same as during the influenza
season (0.47), but there was to few cases to make it significant.
Finally, in your conclusions you make a mistake by stating that typical figures of IPD in developed countries is about 10 per 100.000
per year. That may be so for the whole population, but in the elderly where this calculation is of interest, the correct figure is about 50
per 100.000 per year, thereby reducing the NNT to about 4000 vaccinations per infection avoided.
With the best wishes,
Ake
I certify that I have no affiliations with or involvement in any organisation or entity with a direct financial interest in the subject matter
of my criticisms.
Reply
See reply to comment # 2
Contributors
Ake Ortqvist
Biased assessment of pneumococcal vaccine effect
Summary
The assessment of pneumococcal vaccine in preventing invasive peneumococcal disease (IPD)of this review is biased in favour of the
vaccine and some graphs are misleading.
Take notice that:
No quality assessment has ben made of the observational studies included.
Results of heterogeneous studies are displayed in forest plots (see autoco 06 for instance) where results obtained in young adults are
displayed with results obtained in the elderly. This is not appropriate and is misleading for the not expert.
Assessment of effectiveness of IPV rest on results of Kaufman 1947, no random assignmet, no blind researchers, no placebo group,
only three srotypes vaccine (?); Shapiro 1984, results go in favour of the vaccine when data is unmatched(!). Simm 1988, excluded
46% of subjects because of lack of information and did not provide information on pneumococcus serotypes; Shapiro 1991, excluded
121 cases because were originated by one of the 23 serotypes included in the 23 valent vaccine, but nevertheless reports a non biased
effectiveness in the elderly of 0,6 (IC95% 0,29 yo 1,23); and Butler 1993, no exposure information on 36% of subjects included, a
rate that would invalidate any observational study.
This could go on, but you can go to Puig-Barbera et al to get a much more “Cochrane” description and analysis of the data available.
In our current state of knowledge it cannot be assured that the polysacharide non-conjugated vaccine is free of deleterious effects
in the elderly. Applying the precautionary principle this possibility should be clearly discarded. Meanwhile influenza vaccine does a
tremendous good job preventing pneumonia in the elderly.
I certify that I have no affiliations with or involvement in any organisation or entity with a direct financial interest in the subject matter
of my criticisms.
Reply
We entirely agree that any positive assessment of the vaccine rests on the very old pseudo-randomised trial of Kaufman (1947), and
on the observational studies. However, we do point out the crucial importance of the Kaufman study in the RCT part of our review.
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Our analyses are presented both with and without this study for this reason. Indeed our conclusions from this part of the review are
decidedly negative: for example we suggest that a large RCT carried out now would fail to show any benefit. We include a table showing
how the apparent efficiacy of the vaccine increases monotonically as one progressively includes the poorer quality, older studies, and
point out that several recent high quality randomised studies consistently showed no effect against all-cause pneumonia. Fedson and
Liss have argued that the failure of other meta-analyses to demonstrate a benefit against this outcome should be seen as an inconclusive
rather than negative result on the grounds that, if 30 to 50% of all pneumonias are pneumococcal, a VE of 50% against pneumococcal
pneumonia equates to a VE of 15 to 25% against all-cause pneumonia.(Fedson, 2004) Our results cannot discount this possibility.
We note your concern about the inclusion criteria for observational studies but believe a more fundamental issue was the decision to
incorporate observational studies within the review. Our initial review was conducted in accordance with the protocol. That version of
the review reached a largely negative assessment of the efficacy of polysaccharide pneumococcal vaccines in preventing pneumonia and
death. It was felt by the Editors that this would deliver an unbalanced message, since it made no mention of other important medical
endpoints that the RCTs do not address, in particular invasive pneumococcal disease. The review was therefore expanded specifically
in order to include the observational studies and it could be argued that the impact of this decision was to bias the review in favour
of the vaccine. Whether such a process is proper for a Cochrane Systematic Review is perhaps doubtful but we have still attempted to
assess the evidence fairly. We note that Ave Ortqvist has indicated support for this approach in other comments posted on this review.
Dr Puig-Barbera suggests we should read the paper by Puig-Barbera et al to “get a much more ”Cochrane“ description and analysis
of the data available”. The clear implication here is that our results are biased by the manner in which we included and analysed the
non-randomised studies. It is true that we have not included a formal, numerical assessment of quality of the observational studies.
Probably there is no scale for such studies that would serve as well as the Jadad scale does for RCTs. We have noted the criteria used
for assessment of observational studies by Puig-Barbera et al but do not agree that these criteria are any more valid than the approach
used by us. We note with interest that according to the criteria of Puig-Barbera et al, the study by Forrester et al was rated ahead of
a number of other observational studies and was included when others were excluded. In our review, we have described a number of
serious flaws in Forrester et al, not least of which was the failure to conduct a matched analysis on a matched case control study.
From the paper by Puig-Barbera et al, it appears that the observational studies have been analysed in an unmatched fashion. We believe
this is invalid since, as we have explained in our review, all but one of the observational studies included were matched case-control
studies. For our analysis we combined the estimates of OR based on conditional logistic regression in each study (which accounts for
the matching) and calculated a weighted average log-OR using Stata. Furthermore, it is simplistic to assume that an unmatched analysis
of such studies will always approach the null and that failure to do so represents bias in the study.
We do acknowledge that it might be of value to report the high exclusion rates in the observational studies and are grateful for the
(implied) suggestion. As for the forest plots, they can be stratified in many ways. We suggest that the date of publication is more
important in this regard than the age range of subjects.
We agree with Dr Ortqvist’s suggestion that the NNT should be calculated for the older age group rather than for all adults.
We thank Dr Puig-Barbera and Dr Ortqvist for thier comments, and thank the Comments Editor for permitting this response.
Ross Andrews
John Holden
David Tatham
Keith Dear
I certify that I have no affiliations with or involvement in any organisation or entity with a direct financial interest in the subject matter
of my criticisms.
Contributors
Joan Puig-Barbera
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Reply to comment by Dr Puig-Barbera
Summary
Dear Dr Puig-Barbera,
There are small or big flaws in all studies. The results ot the case-control studies included in the Cochrane analysis are corroborated by
the results of the two most recent prospective studies (Honkanen and our own) where there was a clear trend for a 70-80% protection
of the 23-valent vaccine against bacteremic pneumococcal pneumonia. A similar finding was published in a cohort study, adjusted for
background factors, by Lisa Jackson in NEJM 2003.
Although I agree with you concerning the good effect of influenza vaccine, you’re of course aware of that there is no prospective
controlled study in the elderly showing that influenza vaccine prevents against severe influenza or pneumonia? The only controlled
study showing a protection of the vaccine against clinical (irrespective of severity) and serological influenza.
With the best wishes,
Ake
I certify that I have no affiliations with or involvement in any organisation or entity with a direct financial interest in the subject matter
of my criticisms.
Reply
See reply to comment #2
Contributors
Ake Ortqvist
WH A T ’ S N E W
Last assessed as up-to-date: 3 September 2007.
Date Event Description
9 June 2008 Amended Converted to new review format.
H I S T O R Y
Protocol first published: Issue 2, 1996
Review first published: Issue 4, 2003
Date Event Description
25 July 2004 Feedback has been incorporated Feedback comment added.
23 June 2003 New search has been performed Searches conducted.
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C O N T R I B U T I O N S O F A U T H O R S
Holden (JH) and Tatham (DT) were involved throughout, including the preparation of the protocol, the initial searches for studies
and the assessment of new randomised controlled trials (RCTs) for inclusion in this updated review.
Andrews (RA) joined in May 2001 to assist with incorporating non-RCTs in the review. RA also selected observational studies for this
review update, extracted data and contributed to writing this updated review.
Moberley (SM) joined in 2006 to assist with the update of the review, conducted electronic searches, selected observational studies, re-
extracted data for the additional outcomes in the RCTs, data analysis and wrote this updated review.
D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• St. Helens Multidisciplinary Audit Advisory Group, UK.
• National Health and Medical Research Council (PhD Scholarship Support), Australia.
• Centre for Clinical Research Excellence (PhD Scholarship Support), Australia.
• Menzies School of Health Research, Australia.
External sources
• No sources of support supplied
N O T E S
Included studies
Non-randomised controlled trials (non-RCTs) were only included provided adjustment had been made for important confounding
factors. This essentially excluded studies of vaccine effectiveness utilising the indirect-cohort method.
Of the studies included in the initial review, five studies have been excluded as they did not meet inclusion criteria (one RCT (Honkanen
1999) and four non-RCTs (Butler 1993; Farr 1995; Forrester 1987; MMWR 2001)). Five additional studies have been included in this
update (one RCT (Alfageme 2006) and four non-RCTs (Benin 2003; Jackson 2003; Dominguez 2005; Vila-Corcoles 2006)), bringing
the total number of included studies to 22 (15 RCTs and 7 non-RCTs).
Methods
We revised the outcomes assessed. Primary outcomes are invasive pneumococcal disease (previously, bacteremic pneumococcal pneu-
monia was considered separately), all-cause pneumonia and all-cause mortality.
Subgroup analysis was conducted according to pre-specified characteristics of trial participants that were considered clinically relevant
and would lead to recommendations for vaccination according to different populations at risk of pneumococcal disease. These included
otherwise healthy adults in low income countries, adults with chronic illness in high income countries and otherwise healthy adults in
high income countries.
Findings
When considering all invasive pneumococcal disease, strong evidence of protective efficacy is found in the RCTs.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Case-Control Studies; Pneumococcal Vaccines [∗therapeutic use]; Pneumonia, Pneumococcal [∗prevention & control]; Prospective
Studies; Randomized Controlled Trials as Topic
MeSH check words
Adult; Aged; Humans; Middle Aged
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